Document:

Executive Incentive Compensation Plan

 Exhibit 10.28 

JUNO THERAPEUTICS, INC. 

EXECUTIVE INCENTIVE COMPENSATION PLAN 

Adopted by the Board of Directors on December 2, 2014 

and effective immediately prior to the Company’s initial public offering 

1. Purposes of the Plan. The Plan is intended to increase stockholder value and the success of the Company by motivating Employees to
(a) perform to the best of their abilities, and (b) achieve the Company’s objectives. 
 2. Definitions. 

(a) “Actual Award” means as to any Performance Period, the actual award (if any) payable to a Participant for the Performance
Period, subject to the Administrator’s authority under Section 3(d) to modify the award. 
 (a) “Administrator”
means the Board or any of its Committees as will be administering the Plan, in accordance with Section 5 of the Plan. 
 (b)
“Affiliate” means any corporation or other entity (including, but not limited to, partnerships and joint ventures) controlled by the Company. 

(c) “Board” means the Board of Directors of the Company. 

(d) “Bonus Pool” means the pool of funds available for distribution to Participants. Subject to the terms of the Plan, the
Administrator establishes the Bonus Pool for each Performance Period. 
 (e) “Code” means the Internal Revenue Code of
1986, as amended. Reference to a specific section of the Code or regulation thereunder will include such section or regulation, any valid regulation promulgated thereunder, and any comparable provision of any future legislation or regulation
amending, supplementing or superseding such section or regulation. 
 (f) “Committee” means a committee of one or more
directors and/or officers of the Company appointed by the Board, in accordance with Section 5 hereof. 
 (g) “Company”
means Juno Therapeutics, Inc., a Delaware corporation, or any successor thereto. 
 (h) “Disability” means a permanent and
total disability determined in accordance with uniform and nondiscriminatory standards adopted by the Administrator from time to time. 

 (i) “Employee” means any executive, officer, or key employee of the Company or
of an Affiliate, whether such individual is so employed at the time the Plan is adopted or becomes so employed subsequent to the adoption of the Plan. 

(j) “Fiscal Year” means the fiscal year of the Company. 

(k) “Participant” means as to any Performance Period, an Employee who has been selected by the Administrator for
participation in the Plan for that Performance Period. 
 (l) “Performance Period” means the period of time for the
measurement of the performance criteria that must be met to receive an Actual Award, as determined by the Administrator in its sole discretion. A Performance Period may be divided into one or more shorter periods if, for example, but not by way of
limitation, the Administrator desires to measure some performance criteria over 12 months and other criteria over 3 months. 
 (m)
“Plan” means this Executive Incentive Compensation Plan, as set forth in this instrument and as hereafter amended from time to time. 

(n) “Target Award” means the target award, at 100% performance achievement, payable under the Plan to a Participant for the
Performance Period, as determined by the Administrator in accordance with Section 3(b). 
 (o) “Termination of
Service” means a cessation of the employee-employer relationship between an Employee and the Company or an Affiliate for any reason, including, but not by way of limitation, a termination by resignation, discharge, death, Disability,
retirement, or the disaffiliation of an Affiliate, but excluding any such termination where there is a simultaneous reemployment by the Company or an Affiliate. 

3. Selection of Participants and Determination of Awards. 

(a) Selection of Participants. The Administrator, in its sole discretion, will select the Employees who will be Participants for any
Performance Period. Participation in the Plan is in the sole discretion of the Administrator, on a Performance Period by Performance Period basis. Accordingly, an Employee who is a Participant for a given Performance Period in no way is guaranteed
or assured of being selected for participation in any subsequent Performance Period or Performance Periods. 
 (b) Determination of
Target Awards. The Administrator, in its sole discretion, will establish a Target Award for each Participant (which may be expressed as a percentage of a Participant’s average annual base salary for the Performance Period). 

(c) Bonus Pool. Each Performance Period, the Administrator, in its sole discretion, will establish a Bonus Pool, which pool may be
established before, during or after the applicable Performance Period. Actual Awards will be paid from the Bonus Pool. 
 (d) Discretion
to Modify Awards. Notwithstanding any contrary provision of the Plan, the Administrator may, in its sole discretion and at any time, (i) increase, reduce or eliminate a Participant’s Actual Award, and/or (ii) increase, reduce or
eliminate the amount 

  
 -2- 

 
allocated to the Bonus Pool. The Actual Award may be below, at or above the Target Award, in the Administrator’s discretion. The Administrator may determine the amount of any reduction on
the basis of such factors as it deems relevant, and will not be required to establish any allocation or weighting with respect to the factors it considers. 

(e) Discretion to Determine Criteria. Notwithstanding any contrary provision of the Plan, the Administrator will, in its sole
discretion, determine the performance goals applicable to any Target Award which requirement may include, without limitation, (i) attainment of research and development milestones, (ii) sales bookings, (iii) business divestitures and
acquisitions, (iv) cash flow, (v) cash position, (vi) earnings (which may include any calculation of earnings, including but not limited to earnings before interest and taxes, earnings before taxes, earnings before interested, taxes,
depreciation and amortization and net earnings), (vii) earnings per share, (viii) net income, (ix) net profit, (x) net sales, (xi) operating cash flow, (xii) operating expenses, (xiii) operating income,
(xiv) operating margin, (xv) overhead or other expense reduction, (xvi) product defect measures, (xvii) product release timelines, (xviii) productivity, (xix) profit, (xx) return on assets, (xxi) return on
capital, (xxii) return on equity, (xxiii) return on investment, (xxiv) return on sales, (xxv) revenue, (xxvi) revenue growth, (xxvii) sales results, (xviii) sales growth, (xxix) stock price, (xxx) time to
market, (xxxi) total stockholder return, (xxxii) working capital, (xxxiii) establishing collaboration, research, licensing, manufacturing, or supply arrangements, (xxxiv) patent application filings and patent issuances,
(xxxv) business organizational goals, such a workplace satisfaction, performance evaluations, pay-for-performance, leadership development and succession planning, and (xxxvi) individual objectives such as peer reviews or other subjective
or objective criteria. As determined by the Administrator, the performance goals may be based on generally accepted accounting principles (“GAAP”) or non-GAAP results and any actual results may be adjusted by the Administrator for one-time
items or unbudgeted or unexpected items when determining whether the performance goals have been met. The goals may be on the basis of any factors the Administrator determines relevant, and may be on an individual, divisional, business unit or
Company-wide basis. Any criteria used may be measured on such basis as the Administrator determines, including but not limited to, as applicable, (A) in absolute terms, (B) in combination with another performance goal or goals (for
example, but not by way of limitation, as a ratio or matrix), (C) in relative terms (including, but not limited to, results for other periods, passage of time and/or against another company or companies or an index or indices), (D) on a
per-share basis, (E) against the performance of the Company as a whole or a segment of the Company and/or (F) on a pre-tax or after-tax basis. The performance goals may differ from Participant to Participant and from award to award.
Failure to meet the goals will result in a failure to earn the Target Award, except as provided in Section 3(d). 
 4. Payment of
Awards. 
 (a) Right to Receive Payment. Each Actual Award will be paid solely from the general assets of the Company. Nothing in
this Plan will be construed to create a trust or to establish or evidence any Participant’s claim of any right other than as an unsecured general creditor with respect to any payment to which he or she may be entitled. 

(b) Timing of Payment. Payment of each Actual Award shall be made as soon as practicable after the end of the Performance Period during
which the Actual Award was 

  
 -3- 

 
earned and after the Actual Award is approved by the Administrator, but in no event following the later of (i) the fifteenth (15th) day of the third (3rd) month of the Fiscal Year
immediately following the Fiscal Year in which the Participant’s Actual Award has been earned and no longer is subject to a substantial risk of forfeiture, and (ii) March 15 of the calendar year immediately following the calendar year
in which the Participant’s Actual Award has been earned and no longer is subject to a substantial risk of forfeiture. Unless otherwise determined by the Administrator, to earn an Actual Award a Participant must be employed by the Company or any
Affiliate on the date the Actual Award is paid. 
 It is the intent that this Plan comply with the requirements of Code Section 409A
so that none of the payments to be provided hereunder will be subject to the additional tax imposed under Code Section 409A, and any ambiguities herein will be interpreted to so comply. 

(c) Form of Payment. Each Actual Award will be paid in cash (or its equivalent) in a single lump sum. 

(d) Payment in the Event of Death or Disability. If a Participant dies or becomes Disabled prior to the payment of an Actual Award
earned by him or her prior to death or Disability for a prior Performance Period, the Actual Award will be paid to his or her estate or to the Participant, as the case may be, subject to the Administrator’s discretion to reduce or eliminate any
Actual Award otherwise payable. 
 5. Plan Administration. 

(a) Administrator. Unless and until the Board otherwise determines, the Board will administer the Plan. 

(b) Authority. It will be the duty of the Administrator to administer the Plan in accordance with the Plan’s provisions. The
Administrator will have all powers and discretion necessary or appropriate to administer the Plan and to control its operation, including, but not limited to, the power to (i) determine which Employees will be granted awards,
(ii) prescribe the terms and conditions of awards, (iii) interpret the Plan and the awards, (iv) adopt such procedures and subplans as are necessary or appropriate to permit participation in the Plan by Employees who are foreign
nationals or employed outside of the United States, (v) adopt rules for the administration, interpretation and application of the Plan as are consistent therewith, and (vi) interpret, amend or revoke any such rules. 

(c) Decisions Binding. All determinations and decisions made by the Administrator pursuant to the provisions of the Plan will be final,
conclusive, and binding on all persons, and will be given the maximum deference permitted by law. 
 (d) Delegation. The Board may
delegate authority, in its sole discretion and on such terms and conditions as it may provide, to one or more Committees to administer the Plan. 

(e) Indemnification. Each person who is or will have been a member of the Board or a Committee will be indemnified and held
harmless by the Company against and from 

  
 -4- 

 
(i) any loss, cost, liability, or expense that may be imposed upon or reasonably incurred by him or her in connection with or resulting from any claim, action, suit, or proceeding to which
he or she may be a party or in which he or she may be involved by reason of any action taken or failure to act under the Plan or any award, and (ii) from any and all amounts paid by him or her in settlement thereof, with the Company’s
approval, or paid by him or her in satisfaction of any judgment in any such claim, action, suit, or proceeding against him or her, provided he or she will give the Company an opportunity, at its own expense, to handle and defend the same before he
or she undertakes to handle and defend it on his or her own behalf. The foregoing right of indemnification will not be exclusive of any other rights of indemnification to which such persons may be entitled under the Company’s Certificate of
Incorporation or Bylaws, by contract, as a matter of law, or otherwise, or under any power that the Company may have to indemnify them or hold them harmless. 

6. General Provisions. 

(a) Tax Withholding. The Company will withhold all applicable taxes from any Actual Award, including any federal, state and local taxes
(including, but not limited to, the Participant’s FICA and SDI obligations). 
 (b) No Effect on Employment or Service. Nothing
in the Plan will interfere with or limit in any way the right of the Company to terminate any Participant’s employment or service at any time, with or without cause. For purposes of the Plan, transfer of employment of a Participant between the
Company and any one of its Affiliates (or between Affiliates) will not be deemed a Termination of Service. Employment with the Company and its Affiliates is on an at-will basis only. The Company expressly
reserves the right, which may be exercised at any time and without regard to when during a Performance Period such exercise occurs, to terminate any individual’s employment with or without cause, and to treat him or her without regard to the
effect that such treatment might have upon him or her as a Participant. 
 (c) Participation. No Employee will have the right to be
selected to receive an award under this Plan, or, having been so selected, to be selected to receive a future award. 
 (d)
Successors. All obligations of the Company under the Plan, with respect to awards granted hereunder, will be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase,
merger, consolidation, or otherwise, of all or substantially all of the business or assets of the Company. 
 (e) Beneficiary
Designations. If permitted by the Administrator, a Participant under the Plan may name a beneficiary or beneficiaries to whom any vested but unpaid award will be paid in the event of the Participant’s death. Each such designation will
revoke all prior designations by the Participant and will be effective only if given in a form and manner acceptable to the Administrator. In the absence of any such designation, any vested benefits remaining unpaid at the Participant’s death
will be paid to the Participant’s estate. 
 (f) Nontransferability of Awards. No award granted under the Plan may be sold,
transferred, pledged, assigned, or otherwise alienated or hypothecated, other than by will, by the laws of descent and distribution, or to the limited extent provided in Section 6(e). All rights with respect to an award granted to a Participant
will be available during his or her lifetime only to the Participant. 

  
 -5- 

 7. Amendment, Termination, and Duration. 

(a) Amendment, Suspension, or Termination. The Board, in its sole discretion, may amend or terminate the Plan, or any part thereof, at
any time and for any reason. The amendment, suspension or termination of the Plan will not, without the consent of the Participant, alter or impair any rights or obligations under any Actual Award theretofore earned by such Participant. No award may
be granted during any period of suspension or after termination of the Plan. 
 (b) Duration of Plan. The Plan will commence on the
date specified herein, and subject to Section 7(a) (regarding the Board’s right to amend or terminate the Plan), will remain in effect thereafter. 

8. Legal Construction. 

(a) Gender and Number. Except where otherwise indicated by the context, any masculine term used herein also will include the feminine;
the plural will include the singular and the singular will include the plural. 
 (b) Severability. In the event any provision of the
Plan will be held illegal or invalid for any reason, the illegality or invalidity will not affect the remaining parts of the Plan, and the Plan will be construed and enforced as if the illegal or invalid provision had not been included. 

(c) Requirements of Law. The granting of awards under the Plan will be subject to all applicable laws, rules and regulations, and to
such approvals by any governmental agencies or national securities exchanges as may be required. 
 (d) Governing Law. The Plan and
all awards will be construed in accordance with and governed by the laws of the State of Washington, but without regard to its conflict of law provisions. 

(e) Bonus Plan. The Plan is intended to be a “bonus program” as defined under U.S. Department of Labor regulation 2510.3-2(c)
and will be construed and administered in accordance with such intention. 
 (f) Captions. Captions are provided herein for
convenience only, and will not serve as a basis for interpretation or construction of the Plan. 

  
 -6-Exclusive License Agreement

 Exhibit 10.29 

EXECUTION VERSION 
 [***] CERTAIN INFORMATION
IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

EXCLUSIVE LICENSE AGREEMENT 

THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of December 3, 2014 (the “Execution
Date”), between Juno Therapeutics, Inc., a Delaware corporation (“Juno”), having a place of business at 307 Westlake Ave. N, Suite 300, Seattle, Washington 98109, and Opus Bio, Inc., a Delaware corporation
(“Opus”), having a place of business at 537 Steamboat Road, Suite 200, Greenwich, CT 06830. 
 WHEREAS, Opus has rights in
and to the Licensed IP Rights (as defined below); and 
 WHEREAS, Juno desires to obtain an exclusive license under Opus’s rights in
and to the Licensed IP Rights on the terms and conditions set forth below; 
 NOW, THEREFORE, in consideration of the foregoing premises and
the mutual covenants herein contained, the parties hereby agree as follows: 
 1. DEFINITIONS 

For purposes of this Agreement, the terms defined in this Section 1 shall have the respective meanings set forth below: 

1.1 “Affiliate” means, with respect to any Person, any other Person which directly or indirectly controls, is controlled by,
or is under common control with, such Person. A Person shall be regarded as in control of another Person if it owns, or directly or indirectly controls, at least fifty percent (50%) of the voting stock or other ownership interest of the other
Person, or if it directly or indirectly possesses the power to direct or cause the direction of the management and policies of the other Person by any means whatsoever. The following entities shall be excluded from the definition of Opus Affiliates:
Biomark Capital Fund IV GP LLC and Biomark Capital Fund IV LP and their respective portfolio companies (together, the “Excluded Affiliates”). 

1.2 “Applicable Equity Milestone Amount” means (i) in the case of Milestone #1, [***], (ii) in the case of
Milestone #2, [***] and (iii) in the case of Milestone #3, [***]. 
 1.3 “Applicable Equity Milestone Shares” means,
(a) in respect of any Milestone occurring on or after the date on which the IPO is consummated, a number of shares of Common Stock equal to (i) the Applicable Equity Milestone Amount for such Milestone divided by (ii) the greater of
(A) the arithmetic average of the 30 VWAPs in the applicable Observation Period and (B) the VWAP Floor, or (b) in respect of any Milestone occurring before the date on which the IPO is consummated, at Opus’s option (1) cash
in an amount equal to the Applicable Equity Milestone Amount for such Milestone, or (2) a number of shares of Juno’s senior-most class of capital stock equal to (x) the Applicable Equity Milestone Amount for such Milestone divided by
(y) the greater of (A) the fair market value of one share 

 
of such senior-most class of capital stock as determined in good faith by the board of directors of Juno; provided, however, that if such senior-most class of capital stock is Series B Preferred
Stock, the per share fair market value shall be $2.73, subject to adjustment in the event of a stock split, reverse split, or combination and (B) the VWAP Floor. 

1.4 “BLA” means a Biologic License Application, or similar application for marketing approval of a Product submitted to the
FDA or EMA, or a foreign equivalent. 
 1.5 “Business Day” is any weekday that is not a day on which banking institutions
in New York City are authorized or obligated to close. 
 1.6 “CD-22” means the transmembrane protein with Genebank
accession no. NM_001771, deposited on Sept. 13, 2007 http://www.ncbi.nlm.nih.gov/nuccore/NM_001771, and any variants, isoforms, mutants or derivatives of such protein. 

1.7 “Change of Control” means, with respect to a party, the occurrence of any of the following events: (i) the
acquisition by any Third Party (or a group of Third Parties acting in concert), whether in a single transaction or a series of related transactions, of beneficial ownership of securities of such party representing more than fifty percent
(50%) of the combined voting power of such party’s then outstanding securities entitled to vote generally in the election of directors, provided that (A) such party’s current stockholders shall not be deemed to be acting in
concert by virtue of their current or future ownership of such party’s securities or rights as security holders (including rights to nominate members of such party’s board of directors) and (B) Third Parties who purchase such
party’s securities in future financing transactions, including a public offering, shall not be deemed to be acting in concert by virtue of purchasing the same securities and collectively negotiating, or receiving, their rights as security
holders in such financing transactions; or (ii) the consummation of a merger (including any reverse merger or other similar transaction or series of transactions) or consolidation of such party with a Third Party, which results in such
party’s voting securities outstanding as immediately prior thereto representing (either by remaining outstanding or by being converted into voting securities of the surviving or another entity) fifty percent (50%) or less of the combined
voting power of the voting securities of, as applicable, such party or such surviving or other entity which are outstanding as immediately after such merger or consolidation, or (iii) the bona fide sale, transfer, exclusive license, or other
disposition, whether in a single transaction or series of related transactions, by such party to a Third Party of all or substantially all the assets of such party related to this Agreement. Notwithstanding anything in the foregoing to the contrary,
the IPO shall not be deemed a Change of Control. 
 1.8 “Commercially Reasonable Efforts” means [***]. 

 
 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 2 

 1.9 “Common Stock” shall have the meaning in Section 1.23. 

1.10 “Competent Authority(ies)” means, collectively, (a) the governmental entities in each country or supranational
organization that are responsible for the regulation of any Product, including the granting of Registrations (including the FDA and the EMA), or (b) any other applicable regulatory or administrative agency in any country or supranational
organization that is comparable to, or a counterpart of, the foregoing. 
 1.11 “[***]” means [***]. 

1.12 “Confidential Information” means all secret, confidential or proprietary information or data, whether provided in
written, oral, graphic, video, computer or other form, provided by one party (the “Disclosing Party”) to the other party (the “Receiving Party”) pursuant to this Agreement or generated pursuant to this Agreement,
including information relating to the Disclosing Party’s existing or proposed research, development efforts, patent applications, business or products and any other materials that have not been made available by the Disclosing Party to the
general public. The terms of this Agreement shall be deemed Confidential Information of both Parties. 
 1.13 “Consent”
shall have the meaning in Section 2.5.3. 
 1.14 “Control” means the possession by a party, or any of its Affiliates,
(whether by ownership or license, other than pursuant to this Agreement) of the ability to grant to the other party access, a license, or a sublicense (as applicable) to the applicable patent, patent application, know-how, or other intellectual
property on the terms and conditions set forth herein (a) without violating the terms of any agreement or other arrangement with any Third Party and (b) without being required to make any additional payments or royalties to a Third Party
in connection with such access, license, or sublicense grants, unless the other party agrees to pay the additional payments or royalties to the Third Party (including, in the case of Juno, pursuant to Section 4.6). 

1.15 “Conversion Shares” means shares of Common Stock, if any, reserved by Juno for issuance upon conversion of any Juno
Shares that constitute a series of preferred stock. 
 1.16 “CRADA” means that certain Cooperative Research and Development
Agreement for Intramural-PHS Clinical Research between Neomune, Inc. and the National Cancer Institute, dated September 12, 2012, as amended, numbered CRADA 02821. 
  

[***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 3 

 1.17 “Effective Date” shall have the meaning in Section 10.1. 

1.18 “EMA” means the European Medicines Agency of the European Union, or the successor thereto. 

1.19 “FDA” means the Food and Drug Administration of the United States, or the successor thereto. 

1.20 “First Commercial Sale” means, with respect to any Product, the initial transfer by or on behalf of Juno, its Affiliates
or its sublicensees of any Product in exchange for cash or some equivalent to which value can be assigned for the purpose of determining Net Sales. 

1.21 “IND” means an Investigational New Drug application, or similar application to commence human clinical testing of a
Product submitted to the FDA, or its foreign equivalent. 
 1.22 “Indication” means a specific disease, disorder or
condition which is recognized by the applicable Competent Authorities in a given country or jurisdiction as a separate disease, disorder or condition. For the avoidance of doubt, each type of blood cancer, including each type of leukemia, lymphoma,
or myeloma, including Non-Hodgkins Lymphoma (“NHL”), Acute Myeloid Leukemia (“AML”), Chronic Myeloid Leukemia (“CML”), Acute Lymphocytic Leukemia (“ALL”), Chronic Lymphocytic Leukemia (“CLL”), will
be deemed separate Indications. For the purposes of this Agreement, all subcategories of any such disease, disorder or condition (e.g., refractory, frontline, stage III,, stage IV, adult, or pediatric) will be treated as the same Indication. 

1.23 “IPO” means Juno’s initial public offering of its common stock, $0.0001 par value per share (“Common
Stock”), registered under the Securities Act. 
 1.24 “Juno’s Standard Net Sales Definition” shall have
substantially the same meaning as follows: with respect to any Product, the gross sales price of such Product invoiced by Juno, its Affiliates or its sublicensees to customers who are not Affiliates or sublicensees (except for any Affiliates or
sublicensees who are the end users of such Product) less, to the extent actually paid or accrued by Juno, its Affiliates or sublicensees (as applicable) and actually separately identified on an invoice or other documentation, (a) credits,
allowances, discounts and rebates to, and chargebacks from the account of, such customers for nonconforming, damaged, out-dated and returned Product; (b) freight and insurance costs incurred by Juno, its Affiliates or sublicensees (as
applicable) in transporting such Product to such customers; (c) cash, quantity and trade discounts, rebates and other price reductions for such Product given to such customers under price reduction programs; (d) sales, use, value-added and
other direct taxes incurred on the sale of such Product to such customers; (e) customs duties, tariffs, surcharges and other governmental charges incurred in exporting or importing such Product to such customers; and (f) a reasonable
allowance for uncollectible or bad debts determined in accordance with generally accepted accounting principles. Net Sales shall not include any amounts for Products (i) utilized in any clinical trial, or (ii) provided without charge for
compassionate use, if any. For clarity, Net Sales shall not include sales by 

  
 4 

 
Juno, its Affiliates and sublicensees to Juno, its Affiliates and sublicensees for resale, provided that, if any of such Persons sells Product to another such Person for resale, Net Sales shall
include the amount received by such other Person from Third Parties on the resale of such Product. 
 1.25 “Juno Shares”
means the Applicable Equity Milestone Shares and the shares of Juno’s capital stock issued pursuant to the Stock Purchase Agreement. 

1.26 “Licensed Field of Use” means (a) with respect to rights sublicensed by Opus to Juno hereunder pursuant to Opus
In-License defined in Section 1.35(a), the treatment of B cell malignancies that express CD22 on their cell surface using chimeric antigen receptors which contain the [***] antibody binding fragments; (b) with respect to rights sublicensed
by Opus to Juno hereunder pursuant to Opus In-License defined in Section 1.35(b), the treatment of B cell malignancies that express CD22 on their cell surface using chimeric antigen receptors which contain the [***] antibody binding fragments;
and (c) with respect to rights sublicensed by Opus to Juno hereunder pursuant to Opus In-License defined in Section 1.35(c), the field of use described in clause (a) or (b) of this Section 1.26, as applicable. If the
applicable Opus In-License is amended to expand the applicable field of use, then the Licensed Field of Use shall automatically be commensurately expanded. 

1.27 “Licensed IP Rights” means, collectively, the Licensed Patent Rights and the Licensed Know-How. 

1.28 “Licensed Know-How” means all CRADA Data (as defined in the CRADA), if any, Controlled by Opus or Neomune, Inc., or any
of such Person’s Affiliates, pursuant to the CRADA that are necessary or useful for Juno to make, use, develop, sell or seek regulatory approval to market a composition, or to practice any method or process, at any time claimed or disclosed in
any issued patent or pending patent application within the Licensed Patent Rights. 
 1.29 “Licensed Patent Rights” means
the patents and patent applications Controlled by Opus or Neomune, Inc., or any of such Person’s Affiliates, pursuant to the NIH Patent Licenses, including, to the extent so Controlled, (a) the patents and patent applications listed on
Exhibit A, (b) all divisions, continuations, continuations-in-part, that claim priority to, or common priority with, the patent applications described in clause (a) or the patent applications that resulted in the patents described
in clause (a), and (c) all patents that have issued or in the future issue from any of the foregoing patent applications, including utility, supplemental protection certificates, model and design patents and certificates of invention, together
with any reissues, renewals, extensions or additions thereto. 
 1.30 “Market Disruption Event” means the occurrence or
existence on any Scheduled Trading Day for the Common Stock of any suspension or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the stock exchange or otherwise) in the Common Stock or in any U.S. options
contracts or U.S. futures contracts relating to the Common Stock, and such suspension or limitation occurs or exists at any time within the 30 minutes prior to the closing time of the relevant exchange on such day. 

1.31 “[***]” shall have the meaning in Section 2.2.1. 

 
 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 5 

 1.32 “Net Sales” means the total gross receipts for sales of Products by or on
behalf of Juno or its sublicensees, and from leasing, renting, or otherwise making the Products available to others without sale or other dispositions, whether invoiced or not, less returns and allowances, packing costs, insurance costs, freight
out, taxes or excise duties imposed on the transaction (if separately invoiced), and wholesaler and cash discounts in amounts customary in the trade to the extent actually granted. No deductions shall be made for commissions paid to individuals,
whether they are with independent sales agencies or regularly employed by Juno, or sublicensees, and on its payroll, or for the cost of collections. If the NIH Patent Licenses are amended to incorporate Juno’s Standard Net Sales Definition,
this Agreement shall be amended to use such Net Sales Definition. 
 1.33 “NIH Agreement” shall have the meaning in
Section 3.3.7. 
 1.34 “Observation Period” means in respect of any Milestone, the 30 consecutive Trading Days ending
on the date on which the applicable Milestone was first achieved. 
 1.35 “Opus In-License(s)” means each of the following
agreements (as modified, amended or restated as of the Execution Date or hereafter): (a) that certain Patent License Agreement between the National Institutes of Health (“NIH”) and Neomune, Inc. dated June 25, 2013 with
the License Number L-106-2013; (b) that Patent License Agreement between the NIH and Neomune, Inc. dated June 25, 2013 with the License Number L-107-2013 (collectively, the Patent License Agreements under clauses (a) and (b), the
“NIH Patent Licenses”); and (c) the CRADA. 
 1.36 “Person” means an individual, corporation,
partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically
listed herein. 
 1.37 “Phase I Clinical Trial” means a human clinical trial in any country that is intended to gain
evidence of the safety and tolerability of, and information regarding pharmacokinetics and potential pharmacological activity for, a Product, as described in 21 CFR § 312.21(a), or its foreign equivalent. 

1.38 “Phase II Clinical Trial” means a human clinical trial in any country that is intended to initially evaluate the
effectiveness of a Product for a particular indication or indications in patients with the disease or indication under study or would otherwise satisfy requirements of 21 CFR 312.21(b), or its foreign equivalent. 

1.39 “Phase III Clinical Trial” means a pivotal clinical trial in humans in any country that is intended to gain evidence
with statistical significance of the efficacy of a Product in a target population, and to obtain expanded evidence of safety for such Product that is needed to evaluate the overall benefit-risk relationship of such Product, to form the basis for
approval of a BLA or other regulatory approval and to provide an adequate basis for physician labeling, as described in 21 CFR § 312.21(c), or its foreign equivalent. 
  

[***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 6 

 1.40 “Principal Market” means the NASDAQ Stock Market
(“NASDAQ”), or if the Common Stock is not listed on the NASDAQ, then as reported by the New York Stock Exchange or the principal other national or regional securities exchange on which the shares of the Common Stock are then traded
or, if the Common Stock is not listed or approved for trading on the New York Stock Exchange or another national or regional securities exchange, on the principal market on which shares of the Common Stock are then traded. 

1.41 “Product(s)” means any product that (a) incorporates or uses the Technology, or any modification, improvement or
next generation version of the Technology, and (b) in the course of manufacture, use, sale, offer for sale, or importation, would be within the scope of one or more claims of the Licensed Patent Rights or that otherwise uses or incorporates the
Licensed Know-How. 
 1.42 “Program Costs” means all costs and expenses incurred by Opus and its Affiliates with respect to
the research, development, manufacture, marketing, or other commercialization of the Products during the period between termination and exercise of such option (including any costs paid by Opus to Juno pursuant to Section 10.5.5). Program Costs
will include all out-of-pockets costs, time of scientific, technical, or other personnel (which may be billed on a full-time-equivalent basis at Opus’ and its Affiliates’ normal full-time-equivalent rate, taking into account the reasonable
costs of employment of personnel, including salaries and benefits), and reasonable overhead and indirect costs allocated to the Products, all determined in accordance with generally accepted accounting principles in the United States. 

1.43 “Prosecution and Maintenance” means, with respect to any patent or patent application, the preparing, filing,
prosecuting and maintenance of such patent or application, as well as post grant reviews, inter partes reviews, re-examinations, reissues, requests for patent term extensions and the like with respect to such patents, together with the conduct of
interferences, the defense of oppositions and other similar proceedings with respect thereto; and “Prosecute and Maintain” has the correlative meaning. 

1.44 “Registration(s)” means any and all permits, licenses, authorizations, registrations or regulatory approvals (including
INDs, BLAs, and other Regulatory Approvals) required and/or granted by any Competent Authority as a prerequisite to the development, manufacturing, packaging, marketing and selling of any product, including any separate pricing or reimbursement
approvals that may be legally required in order to sell the product in a particular country. 
 1.45 “Regulatory Approval”
means all approvals, licenses, registrations, or authorizations (including BLAs) of the applicable Competent Authorities in a country necessary for the marketing and sale of a Product in such country, including any separate pricing or reimbursement
approvals that may be legally required. 
 1.46 “Reverse Split” has the meaning set forth in Section 4.2.1. 

1.47 “Royalty Term” means, with respect to each Product in each country, the longest of (a) the term for which a Valid
Claim remains in effect and would be infringed by 

  
 7 

 
such Product in such country but for the license granted by this Agreement, or (b) the period of regulatory data protection or market exclusivity or similar regulatory protection granted by
a Competent Authority for such Product in such country (including any such periods listed in the FDA’s Orange Book or Purple Book, periods under national implementations of Article 10(1)(a)(iii) of Directive 2001/EC/83, and any international
equivalents and including any periods of orphan drug exclusivity). 
 1.48 “Securities Act” means the Securities Act of
1933, as amended. 
 1.49 “Series B Preferred Stock” means Series B Preferred Stock, par value $0.0001 per share, of Juno.

 1.50 “Serious Adverse Drug Experience” means any of an “adverse drug experience,” a “life-threatening
adverse drug experience,” a “serious adverse drug experience,” or an “unexpected adverse drug experience,” as those terms are defined at either 21 C.F.R. § 312.32 or 21 C.F.R. § 314.80 or relevant foreign
regulation within the Territory. 
 1.51 “Stock Purchase Agreement” shall mean that Stock Purchase Agreement, dated as of
the Execution Date, by and between Juno and Opus, a copy of which is attached as Exhibit C. 
 1.52 “Technology”
means any engineered T-cell that is directed against CD-22 (either alone or directed against CD-22 and another target or targets, including a bi-specific). 

1.53 “Territory” means worldwide. 

1.54 “Third Party” means any Person other than Opus, Juno and their respective Affiliates. 

1.55 “Third Party IP Holder” shall have the meaning in Section 3.3.7. 

1.56 “Trading Day” means a day on which (i) there is no Market Disruption Event and (ii) trading in the Common
Stock generally occurs on the Principal Market. If the Common Stock is not so listed or traded, “Trading Day” shall have the same meaning as Business Day. 

1.57 “Valid Claim” means (a) a claim (including a process, use, or composition of matter claim) of an issued and
unexpired patent included within the Licensed Patent Rights or (b) a claim (including a process, use, or composition of matter claim) of a pending patent application included within the Licensed Patent Rights that has not been pending for more
than ten (10) years from the earliest filing date to which such claim or the applicable patent application is entitled to claim priority, in each case under clause (a) or (b) which has not been held permanently revoked, unenforceable
or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and that which has not been admitted to be invalid or unenforceable through reissue or
disclaimer or otherwise. 

  
 8 

 1.58 “VWAP” means the dollar volume-weighted average price for the Common Stock
on the Principal Market during the period beginning at 9:30:01 a.m., New York City time, and ending at 4:00:00 p.m., New York City time, as reported by Bloomberg through its “Volume at Price” function. If VWAP cannot be
calculated for such security on such date, the VWAP of the Common Stock on such date shall be the fair market value as determined in good faith by the board of directors of Juno. All such determinations shall be appropriately adjusted for any share
dividend, share split or other similar transaction during such period. 
 1.59 “VWAP Floor” means $2.73, subject to
adjustment in the event of a stock split, reverse split, or combination. For avoidance of doubt, following the Reverse Split, the “VWAP Floor” shall be adjusted in accordance with the Reverse Split. For example, if the Reverse Split
combines each four shares of Common Stock and each series of Preferred Stock into one share of Common Stock and each series of Preferred Stock, respectively, then the “VWAP Floor” would be $10.92. 

2. REPRESENTATIONS AND WARRANTIES; COVENANTS 

2.1 Mutual Representations and Warranties. Each party hereby represents and warrants to the other party, as of the Execution Date, as
follows: 
 2.1.1 Such party is a corporation duly organized, validly existing and in good standing under the laws of the
state in which it is incorporated. 
 2.1.2 Such party (a) has the corporate power and authority and the legal right to
enter into this Agreement and to perform its obligations hereunder, and (b) has taken all necessary corporate action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. This
Agreement has been duly executed and delivered on behalf of such party, and constitutes a legal, valid, binding obligation, enforceable against such party in accordance with its terms. 

2.1.3 Except for the consents described in Section 2.5, all necessary consents, approvals and authorizations of all
governmental authorities and other Persons required to be obtained by such party in connection with this Agreement have been obtained. 

2.1.4 The execution and delivery of this Agreement and the performance of such party’s obligations hereunder (a) do
not conflict with or violate any requirement of applicable laws or regulations, and (b) do not conflict with, or constitute a default under, any contractual obligation of it. 

2.2 Opus Representations and Warranties. Opus hereby represents and warrants to Juno, as of the Execution Date, as follows: 

2.2.1 Opus (a) is the exclusive licensee of the Licensed Patent Rights for the Field and, subject to Section 3.4,
has not granted to any Third Party any license or other interest in the Licensed IP Rights that would be inconsistent with the 

  
 9 

 
rights granted to Juno under this Agreement; (b) [***] there is no Third Party patent, patent application or other intellectual property rights (including, without limitation, ownership
rights) that would be infringed or otherwise violated by practicing any process or method or by making, using or selling any composition which is claimed or disclosed in the Licensed Patent Rights or which constitutes Licensed Know-How; and
(c) is not aware of any infringement or misappropriation by a Third Party of the Licensed IP Rights. The foregoing representation and warranty excludes any representation and warranty regarding intellectual property rights solely covering that
certain [***]. 
 2.2.2 Subject to Section 2.5, Opus has the right to grant the licenses to the Licensed IP Rights
granted to Juno hereunder, subject to the terms and conditions set forth herein (including the retained rights set forth in Section 3.4). 

2.2.3 Opus has provided Juno with complete and correct copies of all Opus In-Licenses, and there have been no modifications,
amendments or restatements other than as provided to Juno prior to the Execution Date. The Opus In-Licenses are in full force and effect in accordance with their terms. After giving effect to this Agreement, there exist no breaches, defaults or
events by Opus or Neomune, Inc., or any of such Person’s Affiliates, which would (with the giving of notice, the passage of time or both) give rise to a breach, default or other right to terminate or modify any Opus In-License. Opus has not
transferred or granted, and Opus shall not transfer or grant, to any Third Party any license or other interest in the Opus In-Licenses that would be inconsistent with the rights granted to Juno under this Agreement. 

2.2.4 The Licensed IP Rights include all of the patent, know-how, data and other intellectual property rights that Opus or any
of its Affiliates Controls that are necessary or useful to research, develop, make, use, sell, offer for sale or import the Technology, excluding the [***]. Following the Effective Date, Opus shall use [***] to [***]. 

2.2.5 Neither Opus nor Neomune, Inc., nor any of such Person’s Affiliates, has assigned or granted any right or license
to the Technology or Licensed IP Rights to any Excluded Affiliate. Opus is a Delaware corporation formerly known as Lentigen Corporation. Lentigen Corporation’s name was changed 

 
 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 10 

 
to Lenvec Holdings Inc. on August 1, 2014, and to Opus Bio, Inc. on August 12, 2014. Neomune, Inc. is a wholly owned subsidiary of Opus. Opus has or will merge Neomune, Inc. into Opus
on or about the date hereof. Biomark Capital Fund IV LP is the owner of greater than fifty percent (50%) of the voting stock of Opus. 

2.2.6 Opus understands that the Juno Shares and the Conversion Shares, have not been, and will not be, registered under the
Securities Act by reason of a specific exemption from the registration provisions of the Securities Act, the availability of which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of Opus’
representations as expressed herein or otherwise made pursuant hereto. 
 2.2.7 Opus is acquiring the Juno Shares, and the
Conversion Shares, for investment for its own account, not as a nominee or agent, and not with the view to, or for resale in connection with, any distribution thereof, and that Opus has no present intention of selling, granting any participation in,
or otherwise distributing the same. Opus further represents that it does not have any contract, undertaking, agreement or arrangement with any person or entity to sell, transfer or grant participation to such person or entity or to any third person
or entity with respect to any of the Juno Shares or the Conversion Shares. Opus further represents and acknowledges that it became interested in acquiring the Juno Shares and the Conversion Shares as a result of a substantive, pre-existing
relationship with Juno and direct contact with Juno and its agents outside of Juno’s efforts with respect to the IPO, that such interest did not arise by means of either (i) any registration statement filed by Juno with the Securities and
Exchange Commission (including the Registration Statement on Form S-1 (Registration No. 333-200293), as amended) or (ii) any other general solicitation or any other means inconsistent with the availability of an exemption from registration
under Section 4(a)(2) of the Securities Act, and that Opus was not contacted in connection with the marketing of the IPO and did not independently contact Juno as a result of a general solicitation by means of any registration statement filed
by Juno with the Securities and Exchange Commission. 
 2.2.8 Opus has substantial experience in evaluating and investing in
private placement transactions of securities in companies similar to Juno and acknowledges that Opus can protect its own interests. Opus has such knowledge and experience in financial and business matters so that Opus is capable of evaluating the
merits and risks of its investment in Juno. 
 2.2.9 Opus understands and acknowledges that Juno has a limited financial and
operating history and that an investment in Juno is highly speculative and involves substantial risks. Opus can bear the economic risk of its investment and is able, without impairing its financial condition, to hold the Juno Shares and the
Conversion Shares for an indefinite period of time and to suffer a complete loss of its commitment. 
 2.2.10 Opus has had
an opportunity to ask questions of, and receive answers from, the officers of Juno concerning this Agreement, the exhibits and 

  
 11 

 
schedules attached hereto and thereto and the transactions contemplated by the Agreement, as well as Juno’s business, management and financial affairs, which questions were answered to its
satisfaction. Opus believes that it has received all the information it considers necessary or appropriate for deciding whether to purchase the Juno Shares and the Conversion Shares. Opus understands that such discussions, as well as any information
issued by Juno, were intended to describe certain aspects of Juno’s business and prospects, but were not necessarily a thorough or exhaustive description. Opus acknowledges that any business plans prepared by Juno have been, and continue to be,
subject to change and that any projections included in such business plans or otherwise are necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying the projections will not materialize or will vary
significantly from actual results. Opus also acknowledges that it is relying solely on its own counsel and not on any statements or representations of Juno or its agents for legal advice with respect to this investment or the transactions
contemplated by this Agreement. The foregoing, however, does not limit or modify the representations and warranties of Juno in Section 3 of the Stock Purchase Agreement and elsewhere in this Agreement or the right of Opus to rely thereon. 

2.2.11 Opus is an “accredited investor” within the meaning of Regulation D, Rule 501(a), promulgated by the
Securities and Exchange Commission under the Securities Act and shall submit to Juno such further assurances of such status as may be reasonably requested by Juno. 

2.2.12 Opus acknowledges that the Juno Shares and the Conversion Shares must be held indefinitely unless subsequently
registered under the Securities Act or an exemption from such registration is available. Opus is aware of the provisions of Rule 144 promulgated under the Securities Act which permit resale of shares purchased in a private placement subject to the
satisfaction of certain conditions, which may include, among other things, the availability of certain current public information about Juno; the resale occurring not less than a specified period after a party has purchased and paid for the security
to be sold; the number of shares being sold during any three-month period not exceeding specified limitations; the sale being effected through a “brokers’ transaction,” a transaction directly with a “market maker” or a
“riskless principal transaction” (as those terms are defined in the Securities Act or the Exchange Act and the rules and regulations promulgated thereunder); and the filing of a Form 144 notice, if applicable. Opus acknowledges and
understands that notwithstanding any obligation under any agreement between Juno and certain of its shareholders, Juno may not be satisfying the current public information requirement of Rule 144 at the time Opus wishes to sell the Juno Shares or
the Conversion Shares, and that, in such event, Opus may be precluded from selling such securities under Rule 144, even if the other applicable requirements of Rule 144 have been satisfied. Opus acknowledges that, in the event the applicable
requirements of Rule 144 are not met, registration under the Securities Act or an exemption from registration will be required for any disposition of the Juno Shares or the underlying Common Stock. Opus understands that, although Rule 144 is not
exclusive, the Securities and Exchange Commission has expressed its opinion that persons proposing to sell restricted securities received in a private offering other than in a 

  
 12 

 
registered offering or pursuant to Rule 144 will have a substantial burden of proof in establishing that an exemption from registration is available for such offers or sales and that such persons
and the brokers who participate in the transactions do so at their own risk. 
 2.2.13 Opus understands and acknowledges
that no public market now exists for any of the securities issued by Juno and that Juno has made no assurances that a public market will ever exist for Juno’s securities. 

2.2.14 Opus has not engaged any brokers, finders or agents, and neither Juno nor Opus has, nor will, incur, directly or
indirectly, as a result of any action taken by Opus, any liability for brokerage or finders’ fees or agents’ commissions or any similar charges in connection with the Agreements. 

2.2.15 Opus has reviewed with its own tax advisors the U.S. federal, state, local and foreign tax consequences of this
investment and the transactions contemplated by this Agreement. With respect to such matters, Opus relies solely on such advisors and not on any statements or representations of Juno or any of its agents, written or oral. Opus understands that it
(and not Juno) shall be responsible for its own tax liability that may arise as a result of this investment or the transactions contemplated by this Agreement. 

2.2.16 If Opus is (or, as a result of the exercise of its purchase of Juno Shares hereunder, will become) a beneficial owner
of 20% or more of Juno’s outstanding voting securities, calculated on the basis of voting power, Opus affirms that none of (i) Opus, (ii) any of its directors, officers (as defined under Rule 16a-1 promulgated under the Exchange Act),
other officers that may serve as a director or officer of Juno, general partners or managing members, nor (iii) any beneficial owner of Opus which is (or, as a result of the exercise of its purchase of Juno Shares hereunder, will become) a 20%
beneficial owner of the voting securities of Juno (in accordance with Rule 506(d) of the Securities Act) is subject to any of the “bad actor” disqualifications described in Rule 506(d)(1)(i) through (viii) under the Securities
Act (“Disqualification Events”), except for Disqualification Events covered by Rule 506(d)(2)(ii) or (iii) or (d)(3) under the Securities Act and disclosed reasonably in advance of the Closing in writing in reasonable detail to
Juno. 
 2.3 Juno Representations and Warranties. Juno hereby represents and warrants to Opus, as of the Execution Date, as follows:

 2.3.1 Juno (i) is not excluded, debarred or suspended by any Competent Authority, or otherwise ineligible to
participate in federal health care programs such as Medicare or Medicaid or in federal procurement and non-procurement programs, including those produced by the U.S. General Services Administration; or (ii) is not the subject of exclusion,
debarment or suspension proceedings by a Competent Authority or has not been convicted pursuant to Section 306 of the United States Federal Food, Drug and Cosmetic Act, as amended (or similar sanction of a Competent Authority outside the United
States). 

  
 13 

 2.3.2 Juno has the ability and the resources, including financial resources,
necessary to carry out its obligations under this Agreement. 
 2.4 Juno Covenants. Juno hereby covenants to Opus as follows: 

2.4.1 In the course of the development, manufacture, and commercialization of Products under this Agreement, Juno will not use
any employee, agent or independent contractor who has been (i) excluded, debarred or suspended by any Competent Authority, or is otherwise ineligible to participate in federal health care programs such as Medicare or Medicaid or in federal
procurement and non-procurement programs, including those produced by the U.S. General Services Administration; or (ii) is the subject of exclusion, debarment or suspension proceedings by a Competent Authority or has been convicted pursuant to
Section 306 of the United States Federal Food, Drug and Cosmetic Act, as amended (or similar sanction of a Competent Authority outside the United States). 

2.4.2 Juno agrees to conduct development, manufacture, commercialization, and other activities under this Agreement in a good
scientific manner and in compliance in all material respects with applicable law. 
 2.5 Consents. 

2.5.1 The parties acknowledge that the NIH must provide consent to any sublicense under each of the NIH Patent Licenses.
Promptly following the Execution Date, Opus will use reasonable efforts to obtain such consent from the NIH under both NIH Patent Licenses. 

2.5.2 The parties acknowledge that, as of the Execution Date, no CRADA Data is Controlled by Opus or Neomune, Inc., or any of
such Person’s Affiliates, pursuant to the CRADA. Promptly following the Execution Date, Opus will use [***] to amend the CRADA (or otherwise obtain consent) to permit Opus to grant Juno access and a sublicense to the CRADA Data under the terms
of this Agreement and to permit Juno, its Affiliates and sublicensees to exercise the rights granted to Opus or Neomune, Inc., or any of such Person’s Affiliates, pursuant to such CRADA. At a minimum, such amendment or written consent under the
CRADA shall include (a) access to and a copy of any IND that is the subject of the CRADA, (b) access to any and all source data (including but not limited to DMF, CMC, batch records and clinical data) and (c) authority and ability to
cross-reference IND and other related Master Files used with the FDA. 
 2.5.3 The “Consent” shall mean,
collectively, (a) the written consent from the NIH for the grant of sublicenses under both NIH Patent Licenses, including agreement from the NIH providing for a direct license from the NIH to Juno in case any of the NIH Patent Licenses are
terminated, and (b) the written amendment to or written consent under the CRADA to separate the activities under the CRADA that are exclusively related to CD-22 into a new independent cooperative research and development agreement between Juno
and the National Cancer Institute on terms materially consistent with the CRADA. 
  

[***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 14 

 2.6 Disclaimer. Juno understands that the Products are the subject of ongoing research and
development and that Opus cannot assure the safety or usefulness of the Products. In addition, Opus makes no warranties except as set forth in this Article 2 concerning the Licensed IP Rights. 

2.7 No Other Representations or Warranties. EXCEPT AS EXPRESSLY STATED IN THIS ARTICLE 2, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER,
WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, IS MADE OR GIVEN BY OR ON BEHALF OF OPUS. EXCEPT AS
EXPRESSLY STATED IN THIS AGREEMENT, ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED. 

3. LICENSE GRANT 
 3.1
Licensed IP Rights. Subject to the terms and conditions of this Agreement (including Section 3.4), effective as of the Effective Date, Opus hereby grants to Juno an exclusive license (with the right to grant and authorize sublicenses
pursuant to Section 3.2) under the Licensed IP Rights in the Territory to conduct research and to develop, make and have made, to use and have used, to sell and have sold, to offer to sell, to import and to otherwise exploit any Products in the
Licensed Field of Use. If at any time during the term of this Agreement, Opus, or any of its Affiliates, Controls any patent, know-how, data or other intellectual property rights that are necessary or useful to research, develop, make, use, sell,
offer for sale, import or otherwise exploit the Technology (other than [***]) pursuant to Section 2.2.4), then such rights shall automatically be included in the Licensed IP Rights. 

3.2 Sublicensing. The license granted pursuant to Section 3.1 is sublicensable by Juno to any Affiliates or Third Parties;
provided that any such sublicense must comply with the following conditions: 
 3.2.1 Any sublicense must comply with the
requirements of the Opus In-Licenses. 
 3.2.2 Juno may grant sublicenses through multiple tiers but only pursuant to a
written sublicense agreement with the sublicensee. Opus must receive written notice as soon as practicable following execution of any such sublicenses. Any further sublicenses granted by any sublicensees (to the extent permitted hereunder) must
comply with the provisions of this Section 3.2 to the same extent as if Juno granted such sublicense directly. 
 3.2.3
In each sublicense agreement, the sublicensee must be required to comply with the terms and conditions of this Agreement to the same extent as Juno has agreed and must acknowledge that Opus is an express third party beneficiary of such terms and
conditions under such sublicense agreement. 
  
 [***] CERTAIN INFORMATION IN THIS
DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 15 

 3.2.4 The official language of any sublicense agreement shall be English. 

3.2.5 Within [***] after entering into a sublicense, Opus must receive a copy of the sublicense written in the English
language for Opus’ records and to share with the NIH. The copy of the sublicense may be redacted to exclude confidential information of the applicable sublicensee, but such copy shall not be redacted to the extent that it impairs Opus’ (or
the NIH’s) ability to ensure compliance with this Agreement; provided that, if NIH requires a complete, unredacted copy of the sublicense, Juno shall provide such complete, unredacted copy. 

3.2.6 Juno’s execution of a sublicense agreement will not relieve Juno of any of its obligations under this Agreement.
Juno is and shall remain primarily liable to Opus for all of Juno’s duties and obligations contained in this Agreement and for any act or omission of an Affiliate or sublicensee that would be a breach of this Agreement if performed or omitted
by Juno, and Juno will be deemed to be in breach of this Agreement as a result of such act or omission. 
 3.3 Opus In-Licenses. 

3.3.1 Juno acknowledges that the Licensed IP Rights are licensed to Opus pursuant to the Opus In-Licenses and will be
sublicensed to Juno hereunder. In addition to the obligations set forth herein, Juno expressly agrees to be bound by and comply with all applicable provisions of the Opus In-Licenses to the extent such provisions apply to Juno’s, its Affiliates
and its sublicensees’ exploitation of Licensed IP Rights under this Agreement as a sublicensee, including those terms of the NIH Patent Licenses set forth on Exhibit B. Juno agrees to submit and to require its Affiliates and sublicensees
to timely submit or pay (as the case may be) to Opus (or as otherwise directed by Opus) all reports, including development and diligence reports, that a sublicensee is required to submit pursuant to the Opus In-Licenses and all payments that Juno
has agreed to make as set forth in Section 4.6, in each case, to the extent such reports or payments are triggered by or otherwise result from Juno’s, its Affiliates and its sublicensees’ exploitation of Licensed IP Rights under this
Agreement. Unless otherwise agreed, with respect to any reporting and payment obligations under the Opus In-Licenses, Juno (or its Affiliates and sublicensees) shall provide the required reports and payments to Opus at least ten (10) days prior
to the date that any related report or payment is due to NIH as required by the applicable Opus In-License. 
 3.3.2 Opus
promptly shall provide Juno with copies of all notices and other deliveries received from the NIH under the NIH Patent Licenses. Without the prior express written consent of Juno, Opus shall not modify or waive any provision of any Opus In-License
that could reasonably affect Juno’s rights hereunder and shall not terminate any Opus In-License or take any action or refrain from taking any action that could result in a termination of any Opus In-License. 

 
 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 16 

 3.3.3 If either NIH Patent License is terminated for any reason during the term
of this Agreement, the sublicense hereunder with respect to such NIH Patent License will convert to a license directly between Juno and the NIH. 

3.3.4 To the extent there is any conflict between this Agreement and any Opus In-Licenses in respect of Juno’s rights in
the Licensed IP Rights, then, if the conflicting provision of the relevant Opus In-License is more restrictive to Juno’s rights, such conflicting provision of the relevant Opus In-License shall supersede this Agreement as it applies to
Juno’s rights in the Licensed IP Rights. 
 3.3.5 Without limiting the foregoing, Juno understands that
(a) Opus’ rights to the CRADA Data under the CRADA are not exclusive; and (b) if and when such rights are sublicensable to Juno, the exclusive license granted to Juno in Section 3.1 with respect to the Licensed Know-How will be
exclusive as between Opus and Juno, but will not be exclusive as between Juno and Third Parties. 
 3.3.6 Juno acknowledges
and agrees that the Opus In-Licenses constitute Confidential Information of Opus to be held in confidence in accordance with the terms of Section 8. 

3.3.7 Opus agrees to cooperate in good faith with Juno and shall use [***] to assist Juno in facilitating and obtaining a
written agreement with the NIH that would include the following (the “NIH Agreement”): (a) amendments to the NIH Patent Licenses in order to consolidate the two license agreements into one license agreement, or otherwise making
reasonable modifications to diligence obligations such that the diligence obligations for one Product would satisfy diligence obligations for both agreements, and that any delays in achieving the diligence obligations that occur while the NIH is
conducting clinical trials for the Product will be tolled, (b) transferring the IND for the Product to Juno, (c) replacing the Net Sales definition in the NIH Patent Licenses with Juno’s Standard Net Sales Definition and (d) a
representation from the NIH that [***]. 
 3.4 Retained Rights. Except for the rights and licenses specified in Section 3.1, no
license or other rights are granted to Juno under any intellectual property of Opus, whether by implication, estoppel, or otherwise and whether such intellectual property is subordinate, dominant, or otherwise useful for the practice of the Licensed
IP Rights. Notwithstanding anything to the contrary in this Agreement, the licenses granted to Juno pursuant to Section 3.1 and this Agreement are (a) subject to any retained rights of the other 

 
 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 17 

 
parties to the Opus In-Licenses; and (b) subject any and all rights granted by Opus to the National Cancer Institute under the CRADA, including any rights under Sections 7.1 and 10.6
thereof; and Opus retains any and all rights under the Licensed IP Rights necessary for Opus to perform its obligations under the CRADA, including supplying materials thereunder. 

3.5 Delivery and Technical Assistance. Within [***] after the Effective Date, Opus will deliver (and will cause its personnel to
deliver) to Juno a copy of all information in Opus’ possession (in the form then existing) relating to the Licensed IP Rights, including: (a) regulatory submissions, (b) clinical trial protocols, (c) communications with the
Competent Authorities (including the minutes of any meetings), and (d) trial master files, including case report forms. Juno shall reimburse Opus for any reasonable documented out-of-pocket costs (such as copying costs) actually incurred by
Opus in complying with this Section 3.5. For a period of [***] following the Effective Date, Opus shall provide such technical assistance to Juno as Juno reasonably requests regarding the Licensed IP Rights, Products or Technology, including,
if agreed by the parties, providing to Juno all or part of Opus’s inventory of GMP and non-GMP Technology. 
 3.6 Registrations.
Opus acknowledges and agrees that Juno shall own all Registrations for Products in each country in the Territory. Additionally, Opus acknowledges and agrees that Juno shall have the right to conduct pre-clinical and clinical development activities.

 3.7 Access to Manufacturers. Opus shall use [***] to assist Juno in Juno obtaining access directly from any suppliers of any
source materials or components of any Product. 
 3.8 Exclusivity. During the term of this Agreement, and except pursuant to this
Agreement, Opus shall not directly or indirectly (including through an Affiliate or assisting any Third Party) research, develop or commercialize a product that consists of the Technology. 

4. FINANCIAL CONSIDERATIONS 

4.1 License Fees. In partial consideration of Opus’ grant of the rights and licenses to Juno hereunder, Juno shall pay to Opus an
upfront license fee of twenty million dollars ($20,000,000) within [***] Business Days following the Effective Date. 
 4.2 Equity.

 4.2.1 Pursuant to, and subject to the conditions set forth in, the Stock Purchase Agreement, and as consideration of Opus’ grant of
rights and licenses to Juno hereunder, Juno will issue 6,410,256 shares of its capital stock to Opus (as valued at $17,500,000). For the avoidance of doubt, it is acknowledged and agreed that if the Effective Date occurs before the date on which the
IPO is consummated, Juno will deliver 2,747,253 shares of Juno’s Series B Preferred Stock and 3,663,003 shares of Common Stock, and if the Effective Date occurs on or after the date on which the IPO is consummated, Juno will deliver 6,410,256
shares of Common Stock. The parties agree and acknowledge that Juno is contemplating a reverse split of its Common Stock and Preferred Stock (the “Reverse Split”). 

 
 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 18 

 
If the issuance of stock contemplated by this Section 4.2 occurs after the effectiveness of the Reverse Split, the number of shares of Series B Preferred or Common Stock, as applicable, to
be issued to Opus shall be adjusted in accordance with the Reverse Split. For example, if the Reverse Split combines each four shares of Common Stock and each series of Preferred Stock into one share of Common Stock and each series of Preferred
Stock, respectively, then the total number of shares of Series B Preferred Stock and/or Common Stock to be issued to Opus under this Section 4.2 would be 1,602,564. 

4.3 Opus understands and agrees that the securities issued by Juno in connection with the transactions contemplated hereby (including the
Applicable Equity Milestone Shares) and the Stock Purchase Agreement (or any other securities issued in respect thereof up on any stock split, stock dividend, recapitalization, merger, consolidation or similar event), shall bear the following legend
(in addition to any legend required by an agreement entered into in connection therewith or pursuant to applicable state securities laws: 

4.3.1 “THE OFFER AND SALE OF THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR
THE SECURITIES LAWS OF ANY STATE, AND SUCH SECURITIES MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECTED UNLESS AND UNTIL REGISTERED UNDER SUCH ACT AND/OR APPLICABLE STATE SECURITIES LAWS, OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF
COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY AN ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.” 

Furthermore, it shall be a condition to the issuance of any Juno securities pursuant to the Stock Purchase Agreement or hereto (including any
Applicable Equity Milestone Shares) that Opus shall have executed the “market stand-off” agreement set forth on Exhibit D on or prior to the Effective Date. 

4.4 Royalties. 

4.4.1 Royalties will be payable hereunder on a country-by-country and Product-by-Product basis. During the applicable Royalty
Term for a Product, subject to the terms and conditions of this Agreement, Juno shall pay to Opus royalties, with respect to each Product, equal to (a) [***] of annual Net Sales of such Product up to [***], (b) [***] of annual Net Sales of
such Product that are over [***] but less than or equal to [***]; and (c) [***] of annual Net Sales of such Product that are over [***]. For clarity and notwithstanding anything to the contrary, no royalty shall be due or payable in connection
with this Agreement for any Product that is not covered by a Valid Claim in the applicable country of manufacture, sale or use, or has market exclusivity as defined in the definition of Royalty Term. Only one royalty shall be owing for a Product
regardless of how many Valid Claims cover such Product 
 4.5 Combination Products. If a Product is sold as part of a Combination
Product (where “Combination Product” means any product(s) that comprises the Product and 
  

[***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 19 

 
other active compounds, ingredients or components), then for purposes of the royalty payments under Section 4.4 for Net Sales of such Products, such Net Sales shall be determined by
multiplying the Net Sales of the Combination Product (as defined in the standard Net Sales definition) by the fraction “[***],” where A is [***], and B is [***]. If the Product or the other product(s) of the Combination Product [***], then
the Parties shall in good faith determine the value of the other product(s) contained in the Combination Product that is to be deducted from the Net Sales of the Combination Product in determining the Net Sales of the Product contained in the
Combination Product. For clarity, a Product that consists of a single bi-specific CAR to two distinct targets shall not be considered a Combination Product solely because it is a bi-specific. 

4.6 Pass Through Payment to NIH. Juno agrees to pay Opus all amounts owed by Opus under each NIH Patent License, other than
(a) the sublicensing payments set forth in Section V of Appendix C of the NIH Patent Licenses and (b) any amounts payable by Opus to the NIH as a result of liabilities or other damages accrued (including any indemnification obligation)
prior to the Effective Date, or claims arising from actions or omissions occurring prior to the Effective Date, but including royalties on sales of Juno’s, its Affiliates and its sublicensees’ Products or milestone payments triggered,
whether in whole or in part, by the activities of Juno, its Affiliates or its sublicensees, all patent costs, annual minimums, and any other payments due under a NIH Patent License. Juno shall provide the required reports and payments to Opus at
least [***] prior to the date that any related report or payment is due to NIH as required by the applicable Opus In-License. Opus shall remain responsible for all payments owing to the NIH for the sublicensing royalty set forth in Section V of
Appendix C of the NIH Patent Licenses that is due on any consideration received by Opus from Juno under this Agreement. 
 4.7
Milestones. Juno shall pay to Opus the following milestone payments (or issue equity, as applicable) for a Product that is covered by a Valid Claim within [***] following the first achievement of the applicable milestone. The Applicable
Equity Milestone Shares may be uncertificated and shall be registered in the name of Opus by Juno’s stock transfer agent. Each milestone payment shall only be due one time only: 

 

			
	 Milestone Event
	  	 Milestone

Payment

	   1. [***]
	  	Applicable Equity Milestone Shares
	   2. [***]
	  	Applicable Equity Milestone Shares
	   3. [***]
	  	Applicable Equity Milestone Shares
	   4. [***]
	  	[***]

  

[***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 20 

			
	 Milestone Event
	  	 Milestone

Payment

	   5. [***]
	  	[***]
	   6. [***]
	  	[***]
	   7. [***]
	  	[***]
	   8. [***]
	  	[***]
	   9. [***]
	  	[***]
	 10. [***]
	  	[***]
	 11. [***]
	  	[***]
	 12. [***]
	  	[***]

 Without limiting the foregoing, (a) in the event that Milestone #1 has not been paid at the time of achievement of
Milestone #3, then Milestone #1 shall be due immediately, along with the payment of Milestone #3, and (b) in the event that Milestone #2 has not been paid at the time of achievement of Milestone #3, then Milestone #2 shall be due immediately
[***], along with the payment of Milestone #3 and (c) to the extent that Milestone #10 has not been paid at the time of achievement of any of the other Milestones #4 through # 9, then, if the achievement of such other Milestone is for a Product
that [***], then Milestone #10 shall be made in addition to the payment corresponding to the other milestone that has been achieved. 
 Until such time as
Milestone #2 is reached, Juno shall use [***] to obtain reports from the NIH describing the progress made in connection with reaching Milestone #2 and shall promptly provide any such information received from the NIH to Opus. 

If Opus is unable to secure the representation from the NIH as set forth in Section 3.3.7 (d) above, then to the extent Juno, its Affiliates,
sublicensees, suppliers, manufacturers or collaborators (the “Juno Parties”) are required [***]. 
 5. ROYALTY REPORTS
AND ACCOUNTING 
 5.1 Royalty Reports. Within [***] days after the end of each [***] during the term of this Agreement following
the First Commercial Sale of a Product, Juno shall furnish to Opus a [***] written report showing in reasonably specific detail (a) the calculation of Net Sales during such [***]; (b) the calculation of the royalties, if any, that shall
have accrued based upon such Net Sales; (c) the withholding taxes, if any, deducted in accordance with Section 6.3 with respect to such sales; and (d) the exchange rates, if any, used in 

 
 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 21 

 
determining the amount of United States dollars in accordance with Section 6.2. With respect to sales of Products invoiced in United States dollars, the gross sales, Net Sales and royalties
payable shall be expressed in United States dollars. With respect to Net Sales invoiced in a currency other than United States dollars all such amounts shall be expressed both in the currency in which the distribution is invoiced and in the United
States dollar equivalent. For conversion of foreign currency to United States dollars, the conversion rate shall be the New York foreign exchange rate quoted in The Wall Street Journal on the day that the payment is due. Any loss of exchange,
value, taxes, or other expenses incurred in the transfer or conversion to United States dollars shall be paid entirely by Juno. 
 5.2
Audits. 
 5.2.1 Upon the written request of Opus and not more than [***] in each [***], Juno shall permit an
independent certified public accounting firm of nationally recognized standing selected by Opus and reasonably acceptable to Juno, at Opus’s expense, to have access at Juno’s facilities during normal business hours to such of the financial
records of Juno as may be reasonably necessary to verify the accuracy of the royalty reports hereunder for the [***] immediately prior to the date of such request (other than records for which Opus has already conducted an audit under this Section).

 5.2.2 If such accounting firm determines that additional royalties were owed under this Agreement during the audited
period, Juno shall pay any undisputed royalties within [***] after the date Opus delivers to Juno such accounting firm’s written report containing such determinations. The fees and expenses charged by such accounting firm shall be paid by Opus;
provided, however, if the audit determines that the royalties payable by Juno for such period are underpayment is more than [***] of the amount of the royalties actually paid for such period, then Juno shall pay the reasonable fees and expenses
incurred by Opus for such audit. 
 5.2.3 Opus shall cause the accounting firm to retain all financial information subject
to review under this Section 5.2 in confidence in accordance with Article 8; provided, however, that Juno shall have the right to require that such accounting firm, prior to conducting such audit, enter into a reasonable non-disclosure
agreement with Juno regarding such financial information. The accounting firm shall disclose to Opus only whether the reports are correct or not in their determination and the amount of any alleged discrepancy. No other information shall be shared
with Opus. Opus shall treat all such financial information as Juno’s Confidential Information. 
 6. PAYMENTS 

6.1 Payment Terms. Royalties shown to have accrued by each royalty report provided for under Section 5 shall be due [***] such
royalty report is due. Payment of royalties in whole or in part may be made in advance of such due date. 
  

[***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 22 

 6.2 Exchange Control. If at any time legal restrictions relating to the transfer of
foreign currency out of a country prevent the prompt remittance of part or all royalties with respect to any country in the Territory where the Product is sold, Juno shall have the right, in its sole discretion, to make such payments by depositing
the amount thereof in local currency to an account in Opus’ name and under Opus’ sole control in a bank or other depository institution in such country, which bank or other institution must be reasonable acceptable to Opus. If the royalty
rate specified in this Agreement should exceed the permissible rate established in any country, the royalty rate for sales in such country shall be adjusted to the highest legally permissible or government-approved rate. 

6.3 Withholding Taxes. 

6.3.1 All payments hereunder will be made free and clear of, and without deduction or deferment in respect of, and Juno shall
pay and be responsible for, and shall hold Opus harmless from and against, any taxes, duties, levies, fees, or charges, including sales, use, transfer, excise, import, and value added taxes (including any interest, penalties, or additional amounts
imposed with respect thereto) but excluding withholding taxes to the extent provided in Section 6.3.2. At the request of Juno, Opus will give Juno such reasonable assistance, which will include the provision of documentation as may be required
by the relevant tax authority, to enable Juno to pay and report and, as applicable, claim exemption from or reduction of, such tax, duty, levy, fee, or charge. 

6.3.2 If any payment made by Juno hereunder becomes subject to withholding taxes with respect to Opus’ gross or net
income under the laws of any jurisdiction, Juno will deduct and withhold the amount of such taxes for the account of Opus to the extent required by law and will pay the amounts of such taxes to the proper governmental authority in a timely manner
and promptly transmit to Opus appropriate proof of payment of such withholding taxes. At the request of Opus, Juno will give Opus such reasonable assistance, which will include the provision of appropriate certificates of such deductions made
together with other supporting documentation as may be required by the relevant tax authority, to enable Opus to claim exemption from or reduction of, or otherwise obtain repayment of, such withholding taxes, and will upon request provide such
additional documentation from time to time as is reasonably required to confirm the payment of withholding tax. 
 7. RESEARCH AND
DEVELOPMENT OBLIGATIONS  
 7.1 Research and Development Efforts. Juno shall use Commercially Reasonable Efforts to research,
develop (including preclinical and human clinical trials), manufacture, market, and otherwise commercialize Products in the Territory, including using Commercially Reasonable Efforts to obtain Registrations for the Products. Without limiting the
forgoing, this obligation shall include using Commercially Reasonable Efforts to obtain Regulatory Approval (a) in [***] and (b) in [***], if the scientific and regulatory data support development and commercialization of the Product in
[***]. Upon obtaining a Regulatory Approval for the Product in a country, Juno shall use Commercially Reasonable Efforts to 
  

[***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 23 

 
commence marketing and selling the Product in such country within [***] following receipt of such Regulatory Approval. Notwithstanding the foregoing, if Juno obtains Regulatory Approval in a
country but delays marketing and selling the Product in such country as part of a phased roll-out or due to insufficient pricing or reimbursement approvals, then such delay shall be deemed not a failure to use Commercially Reasonable Efforts.
Commencing with the full calendar year following the earlier of (a) achievement of the Satisfactory Outcomes (as defined below), or (b) [***], Juno shall spend at least two million five hundred thousand dollars ($2,500,000) during each
full calendar year to research, develop (including preclinical and human clinical trials), manufacture, market, and otherwise commercialize Products in the Territory. “Satisfactory Outcomes” means that both (i) [***], and
(ii) [***]. 
 7.2 Additional Diligence Obligations. Without limiting the foregoing, Juno agrees to the following: 

(a) Juno will develop Products in accordance with the Commercial Development Plans of each NIH Patent License, as such plans may be modified
upon the agreement of Juno and Opus, and with the consent of the NIH in accordance with the applicable NIH Patent License. 
 (b) Any
failure by Juno to comply with the timelines set forth on Exhibit E will be deemed to be a material breach of this Agreement, for which Opus may exercise its termination rights under Section 10.4, in addition to any other available
remedies at law or in equity. The parties may amend the benchmarks set forth on Exhibit E upon mutual consent. Opus will not unreasonably withhold approval of any request of Juno to extend the time periods for the benchmarks if (i) the
request is supported by a reasonable showing by Juno of diligence in its performance under the Commercial Development Plan and toward bringing the Products to the point of Practical Application (as defined in the NIH Patent License), and
(ii) the NIH agrees to an extension of the applicable benchmarks under the applicable NIH Patent License. Upon receipt of such consent from the NIH, the benchmarks on Exhibit E shall be automatically and commensurately amended. 

(c) Juno will amend the Commercial Development Plan and benchmarks described in this Section 7.2 at the request of the NIH, and to the
extent required under the applicable Opus-In Licenses, to address any fields of use not specifically addressed in the plan originally submitted. 

7.3 Reports. Within [***] following [***] of each calendar year during the term of this Agreement, Juno shall prepare and deliver to
Opus a written summary report that shall describe (a) the research performed to date employing the Licensed IP Rights, (b) the progress of the development, and testing of Products in clinical trials, (c) the status of obtaining
Registrations for the Products, and (d) such additional information with respect to Juno’s activities under this Agreement as is necessary for Opus to comply with the terms of Section 9.2 of the NIH Patent Licenses. Juno will notify
Opus within [***] of the achievement of each benchmark set forth on Exhibit E. 
  

[***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 24 

 8. CONFIDENTIALITY 

8.1 Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, each party agrees that,
for the term of this Agreement and for [***] thereafter, such party shall keep Confidential Information of the Disclosing Party confidential and otherwise shall not disclose or use such Confidential Information for any purpose other than as provided
for in this Agreement; provided that the obligations of this Section 8.1 shall not apply to the extent that the Receiving Party can demonstrate by competent written proof that the Confidential Information of the Disclosing Party: 

8.1.1 was already known to the Receiving Party (other than under an obligation of confidentiality), at the time of disclosure
by the Disclosing Party to the extent such Receiving Party has documentary evidence to that effect; 
 8.1.2 was generally
available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party; 

8.1.3 became generally available to the public or otherwise part of the public domain after its disclosure or development, as
the case may be, and other than through any act or omission of a party in breach of such party’s confidentiality obligations under this Agreement; 

8.1.4 was subsequently lawfully disclosed to the Receiving Party by a Third Party who had no obligation to the Disclosing
Party not to disclose such information to others; 
 8.1.5 was independently discovered or developed by or on behalf of the
Receiving Party without the use of the Confidential Information belonging to the other party and the Receiving Party has documentary evidence to that effect; or 

8.1.6 is approved for release by the Disclosing Party in writing. 

8.2 Authorized Disclosure. 

8.2.1 Each party may disclose Confidential Information belonging to the other party to the extent such disclosure is
reasonably necessary in the following situations: 
 (a) prosecuting or defending litigation; 

(b) in the case of Juno as the Receiving Party, filing or prosecuting patents and patent applications; 

(c) in the case of Juno as the Receiving Party, regulatory filings with Competent Authorities for purposes of obtaining Registrations for
Products; 
  
 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 25 

 (d) complying with applicable laws and regulations, including regulations promulgated by
securities exchanges; 
 (e) disclosure to its Affiliates and potential or actual sublicensees, and any of its and their directors,
officers, employees, agents, partners, including limited partners, and independent contractors, and any bona fide potential or actual licensees or collaborators only on a need-to-know basis and solely as necessary in connection with the performance
of, and exercise of rights under, this Agreement; provided that each Person receiving such Confidential Information must be bound by written obligations of confidentiality and non-use at least as restrictive in scope as those set forth in this
Article 8 prior to any such disclosure; and 
 (f) disclosure of the material terms of this Agreement to any bona fide potential or actual
investor, investment banker, acquirer, merger partner, or other potential or actual financial partner; provided that each Person receiving such Confidential Information must be bound by written obligations of confidentiality and non-use at least as
restrictive in scope as those set forth in this Article 8 prior to any such disclosure. 
 8.2.2 Notwithstanding the foregoing, in the
event a Receiving Party is required to make a disclosure of the Disclosing Party’s Confidential Information pursuant to Section 8.2.1(a) or 8.2.1(d), such Receiving Party will (i) give reasonable advance notice to the Disclosing Party
of such disclosure in order to provide the Disclosing Party an opportunity to take legal action to prevent or limit such disclosure, and (ii) use reasonable efforts to secure confidential treatment of such information. In any event, the parties
agree to take all reasonable action to avoid disclosure of Confidential Information hereunder. In connection with any disclosures of Confidential Information pursuant to Section 8.2.1(e) or 8.2.1(f), the Receiving Party will be responsible for
any breaches of the confidentiality obligations hereunder by any such Persons to whom the Receiving Party discloses the Disclosing Party’s Confidential Information under such subsections. 

8.3 Return of Confidential Information. Upon termination (but not expiration) of this Agreement the Receiving Party shall promptly
return all of the Disclosing Party’s Confidential Information, including all reproductions and copies thereof in any medium, except that the Receiving Party may retain one copy for its legal files; provided that the Receiving Party may retain
any Confidential Information licensed to the Receiving Party to the extent such license survives termination. 
 8.4 Unauthorized
Use. If either party becomes aware or has knowledge of any unauthorized use or disclosure of the other party’s Confidential Information, it shall promptly notify the Disclosing Party of such unauthorized use or disclosure. 

8.5 Public Announcements. Neither Opus nor Juno shall make any public announcement regarding this Agreement, without the prior written
consent of the other party, which consent will not be unreasonably withheld or delayed, unless required by law, and then only after complying with Section 8.2. The forgoing notwithstanding, the parties intend to each issue a press release
regarding this Agreement within 48 hours after the Execution Date. Neither party shall issue and such press release without the consent of the other Party, such consent not to be not be unreasonably withheld or delayed. 

  
 26 

 9. PATENTS 

9.1 Prosecution and Maintenance of Licensed Patent Rights. As between the parties but subject to any rights and obligations of Opus to
the NIH, the parties agree as follows: 
 9.1.1 Juno shall, [***] use commercially reasonable efforts to Prosecute and
Maintain the Licensed Patent Rights, using patent counsel of its choice reasonably acceptable to Opus. Promptly after the Effective Date, subject to the terms of this Section 9.1, Juno shall assume control of the Prosecution and Maintenance of
the Licensed Patent Rights. Juno shall keep Opus reasonably informed regarding matters related to the Prosecution and Maintenance of each patent or patent application within the Licensed Patent Rights and provide Opus the reasonable opportunity to
review and comment in advance on material submissions to any patent office relating thereto, and shall in good faith consider such comments before making any such material submissions. Juno shall provide copies of all correspondence relating to
prosecution of Licensed Patent Rights to Opus. 
 9.1.2 If Juno elects to abandon any patent or patent application within
the Licensed Patent Rights, it shall notify Opus at least [***] in advance of any relevant deadline or event relating to any such Licensed Patent Right, in which case Opus shall have the right (but not the obligation) to control the Prosecution and
Maintenance of such patents and applications (including any patent issuing therefrom), [***]. From and after the effective date of such notice, such patent or patent application shall cease to be within the Licensed Patent Rights for all purposes of
this Agreement, and all rights and obligations of Juno (including the obligation to pay costs associated with Prosecution and Maintenance) with respect thereto shall terminate and revert to Opus. 

9.1.3 Juno acknowledges that the NIH controls Prosecution of the Licensed Patent Rights, with Opus having certain rights to
review. Juno acknowledges and agrees that (a) the rights and obligations under this Section 9.1 are subject to the rights of the NIH with respect to the Licensed Patent Rights, and (b) Opus’ obligations under this Agreement only
apply to the extent of Opus’ rights with respect to participation in Prosecuting the Licensed Patent Rights under the NIH Patent Licenses, and Opus will grant to Juno all rights that Opus receives under the NIH Patent Licenses. [***]. 

9.2 Notification of Infringement. If either party reasonably believes that any Licensed Patent Right is being infringed by a Third
Party or is subject to a declaratory judgment action arising from such infringement, in each case with respect to the manufacture, use, sale, offer for sale or importation of any product or the provision of any service in the Territory, such party
shall promptly notify the other party in writing describing the facts relating thereto in reasonable detail. 
  

[***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 27 

 9.3 Enforcement of Patent Rights. As between the parties but subject to any rights and
obligations of Opus to the NIH, the parties agree as follows: 
 9.3.1 Juno. Juno shall have the initial right, but
not the obligation, to institute, prosecute and control any such action, suit or proceeding to enforce such Licensed Patent Rights with respect to such infringement, or to defend any declaratory judgment action with respect to any Licensed Patent
Rights (each, an “Action”) [***], using legal counsel of its choice (and reasonably acceptable to Opus), and Opus shall reasonably cooperate with Juno in connection with any such Action, [***]; provided Juno may not enter into any
settlement which admits that any of the Licensed Patent Rights is invalid or unenforceable without Opus’s prior written consent. Any amounts recovered from Third Parties in any such Action shall be used first to [***], and the remainder shall
be [***]. 
 9.3.2 Opus. If Juno fails to initiate or defend any Action with respect to any commercially significant
infringement of any Licensed Patent Rights within [***] of a request by Opus to do so (or such shorter period of time as required under statute in order to preserve Opus’ ability to initiate or defend any such Action or to preserve the remedies
that may be obtained (including monetary and injunctive relief) in such Action), Opus shall have the right, but not the obligation, to initiate or defend such an Action, [***] using legal counsel of its choice; provided Opus may not enter into any
settlement which admits that any of the Licensed Patent Rights is invalid or unenforceable without Juno’s prior written consent. Any amounts recovered from Third Parties in any such Action shall be used first to [***], and the remainder shall
be [***]. 
 9.3.3 NIH. Juno acknowledges and agrees that (i) the rights and obligations under this
Section 9.3 are subject to the rights of the NIH (including any consent or approval rights or rights to control or participate in any enforcement actions); and (ii) Opus’ obligations under this Agreement only apply to the extent that
Opus has any rights with respect to enforcing the Licensed Patent Rights under the NIH Patent Licenses, and Opus will grant to Juno all rights that Opus receives under the NIH Patent Licenses. Furthermore, Juno acknowledges the following: 

(a) All monies recovered in any Action will also need to be allocated to the NIH in accordance with the terms of the NIH Patent Licenses.

 (b) The NIH’s first right to pursue legal action and continuing right to intervene and join Opus or Juno in any Action. 

9.4 Cooperation. In any Action in connection with the enforcement and/or defense of the Licensed Patent Rights, the non-controlling
party shall, at the request [***] of the controlling party, cooperate fully, including by joining as a party plaintiff and executing such documents as the controlling party may reasonably request. Furthermore, at the controlling party’s request
[***], the non-controlling party shall make available at reasonable times and under appropriate conditions all relevant records, papers, information, samples and other similar materials in its possession, and to the extent possible, have its
employees testify when requested. 
  
 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 28 

 9.5 Common Interest Disclosures. With regard to any information or opinions disclosed
pursuant to this Agreement by one party to the other party regarding intellectual property and/or technology owned by Third Parties, Juno and Opus agree that they have a common legal interest in determining whether, and to what extent, Third Party
intellectual property rights may affect the practice of the Licensed IP Rights and Technology, and have a further common legal interest in defending against any actual or prospective Third Party claims based on allegations of misuse or infringement
of intellectual property rights relating to the practice of the Licensed IP Rights and Technology. Accordingly, Juno and Opus agree that all such information and materials obtained by Juno and Opus from each other shall be used solely for purposes
of the parties’ common legal interests with respect to the conduct of the Agreement. All information and materials shall be treated as protected by the attorney-client privilege, the work product privilege, and any other privilege or immunity
that may otherwise be applicable, except with respect to disputes arising between the parties. By sharing any such information and materials, neither party intends to waive or limit any privilege or immunity that may apply to the shared information
and materials. Neither party shall have the authority to waive any privilege or immunity on behalf of the other party without such other party’s prior written consent, nor shall the waiver of privilege or immunity resulting from the conduct of
one party be deemed to apply against any other party. 
 9.6 Marking. To the extent commercially viable, Juno agrees to mark the
Products or their packaging or inserts or information websites sold in the United States with all applicable U.S. patent numbers and similarly to indicate “Patent Pending” status. All Products manufactured in, shipped to, or sold in other
countries shall be marked in a manner to preserve Opus’ and the NIH’s patent rights in those countries. 
 10. TERMINATION

 10.1 Effectiveness. Except for the parties’ obligations under Article 8, Opus’ obligations under Section 2.5, 3.3.2
and 3.3.7, 3.8 and 10.1 and the parties’ representations and warranties (and disclaimers thereof) in Sections 2.1, 2.2, 2.3, and 2.6, this Agreement shall not become effective until Opus has delivered to Juno the Consent (the date of delivery,
the “Effective Date”). If the Effective Date has not occurred within one hundred and twenty (120) days of the Execution Date, Juno may terminate this Agreement at any time prior to the Effective Date upon written notice to Opus;
provided further that if Juno has not terminated and the Effective Date has not occurred within one hundred and eighty days (180 days), either party may terminate upon written notice to the other. Prior to the Effective Date, Opus will not (and will
assure that its officers, directors, employees, agents and affiliates do not on its behalf) take any action to solicit, initiate, seek, encourage or support any inquiry, proposal or offer from, furnish any information to, or participate in any
negotiations with, any Person (other than discussions with Juno) regarding any acquisition, license, assignment or any grant of rights of any portion of the Technology, or any acquisition of Opus and/or its Affiliates (each, a “Third Party
Transaction”). Opus agrees that any such negotiations in progress as of the date hereof will be terminated or suspended. 

  
 29 

 10.2 Expiration. Subject to Sections 10.3 and 10.4 below, this Agreement shall expire on
the expiration of Juno’s payment obligations to Opus or to the NIH hereunder. Upon such expiration of this Agreement (but not in the event of earlier termination), Juno shall have a fully paid-up, non-exclusive license under the Licensed
Know-How of the same scope as in Section 3.1. 
 10.3 Termination by Juno. Juno may terminate this Agreement, in its sole
discretion, upon [***] prior written notice to Opus. 
 10.4 Termination for Cause. 

10.4.1 Except as otherwise provided in Section 12, Opus may terminate this Agreement upon or after the breach of any
material provision of this Agreement by Juno if Juno has not cured or discontinued such breach within [***] after receipt of express written notice thereof by Opus to Juno (or [***] if such breach is a failure to pay any amounts due hereunder). 

10.4.2 If Juno files for protection under bankruptcy laws, makes an assignment for the benefit of creditors, appoints or
suffers appointment of a receiver or trustee over its property, files a petition under any bankruptcy or insolvency act, or has any such petition filed against it which is not discharged within [***] of the filing thereof, then Opus may terminate
this Agreement effective immediately upon written notice to Juno. 
 10.5 Effect of Expiration or Termination. 

10.5.1 Expiration or termination of this Agreement shall not relieve the parties of any obligation accruing prior to such
expiration or termination (including all accrued payment obligations), and the provisions of Sections 2.6, 2.7, 3.3.1 (to the extent of any continuing obligations under the Opus In-Licenses), 3.3.6, 5.1 (for purposes of Juno filing a final royalty
report for Net Sales through the termination or expiration of this Agreement), 5.2, 8, 9.5, 10, 11 and 13 shall survive the expiration or termination of this Agreement. 

10.5.2 If this Agreement is terminated for any reason, any Third Party sublicensee of Juno hereunder who is in full compliance
with the terms and conditions of the sublicense shall be entitled to become a direct licensee of Opus under the terms of this Agreement with respect to the rights sublicensed by Juno to the sublicensee (including the territory and products);
provided that, as a condition of receiving such direct license from Opus, (a) the sublicensee must not be in material breach of its sublicense, (b) the sublicensee did not contribute by any act or omission to a breach of this Agreement by
Juno that, if applicable, led to the termination of this Agreement, and (c) the sublicensee must agree to assume all of Juno’s future obligations (i.e., obligations after becoming such direct licensee) under this Agreement with respect to
the rights sublicensed by Juno to the sublicensee, to the extent relating to the activities of the sublicensee. 
  

[***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 30 

 10.5.3 Upon termination of this Agreement for any reason, except as provided in
this Article 10, all rights and licenses granted to Juno (including all licenses under Section 3.1) will terminate. 

10.5.4 Unless this Agreement is terminated by Juno pursuant to Section 10.3 or by Opus pursuant to Section 10.4,
Juno shall have the right to sell or otherwise dispose of all Products in the process of manufacture, testing, in use or in stock for a period of [***] from such termination; provided that Juno shall remain obligated to make payment of royalties to
Opus for such Products in accordance with Article 4. 
 10.5.5 Upon termination of this Agreement by Juno pursuant to
Section 10.3 or by Opus pursuant to Section 10.4: 
 (a) Juno shall [***], transfer to Opus all Product and all related reagents,
intermediates, or other materials, including vector or other transduction materials, it has on hand related to the Product and any ongoing or contemplated clinical trials. Juno shall also manufacture the Product for Opus in a manner materially
consistent with Juno’s efforts to manufacture other engineered T-cells for its own purposes pursuant to terms and conditions customary in pharmaceutical manufacturing agreements, including IP warranties and indemnification obligations. Opus
shall reimburse Juno at a transfer price equal to [***] of Juno’s fully burdened cost to manufacture the Product (as determined in accordance with generally accepted accounting principles in the United States). Without limiting Juno’s
binding obligation to manufacture the Product, the Parties may, subject to mutual agreement, enter into additional agreements regarding Juno’s manufacture of Products. 

(b) Juno will transfer to Opus ownership of any Registrations and related documentation (including drug dossiers) to the extent [***] (the
“Subject Registrations”), explicitly excluding i) [***], and ii) [***] (with respect to clause (i) and clause (ii), the “Excluded Registration Materials”). Juno will notify the appropriate Competent Authorities
of transfer of ownership. Juno hereby grants (effective only upon any such termination of this Agreement) to Opus a non-exclusive, worldwide, royalty-free, transferable, irrevocable, perpetual right of access and reference (with the right to grant
sublicenses (through multiple tiers)) to the Excluded Registration Materials solely to the extent necessary for Opus to market and sell the Products solely to the extent manufactured by Juno. If ownership of any of the Subject Registrations cannot
be transferred to Opus in any country, Juno hereby grants (effective only upon any such termination of this Agreement and only with respect to any Subject Registration that cannot be transferred) to Opus an exclusive (even as to Juno), worldwide,
royalty-free, transferable, irrevocable, perpetual right of access and reference (with the right to grant sublicenses (through multiple tiers)) to any such Subject Registration solely to the extent necessary for Opus to market and sell the Products.

  
 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 31 

 (c) Juno shall grant, and hereby grants (effective only upon any such termination of this
Agreement), to Opus a non-exclusive, worldwide, royalty-free, transferable, irrevocable, perpetual license, with the right to grant sublicenses (through multiple tiers), under the Juno Technology to conduct research and to develop, make, have made,
use, offer for sale, sell, import and otherwise exploit the Products in the Territory. For this purpose, the “Juno Technology” means, [***]. To effectuate such license, upon any such termination of this Agreement, Juno will promptly
disclose to Opus all Juno Technology not already known to Opus to the extent [***]. For the avoidance of doubt, nothing in this Section 10.5.5(c) shall prevent Opus from creating improvements to Products, provided that, the scope of the Juno
Technology included in the license set forth in this Section 10.5.5(c) is strictly limited to the Juno Technology as [***]. For clarity, to the extent Juno Technology exists as of the effective date of termination and is not [***], then such
Juno Technology shall not be included within the scope of such license. 
 (d) On a country-by-country basis, Juno will transfer to Opus
ownership of any trademarks or brand names of Juno’s, its Affiliates,’ or its sublicensees (other than any house mark) that have been approved for use with any Product by the applicable Competent Authority in such country. 

(e) Juno will use commercially reasonable efforts to assign to Opus all third party agreements to the extent that they relate solely to the
Products and are necessary for the research, development, marketing, or other commercialization of the Products in the Territory, other than any such third party agreement related to Juno’s [***] (including the Excluded Registration Materials).

 (f) At Opus’ option, Opus will be entitled to assume any clinical trials being conducted by Juno, its Affiliates, or sublicensees
with respect to the Products, and Juno, at Opus’ expense, will provide Opus with reasonable consultation and assistance to transition such clinical trials to Opus, including assigning any applicable agreements related thereto. 

(g) Opus will have the right, upon written notification to Juno, to purchase, at the cost of goods (as determined in accordance with
generally accepted accounting principles in the United States), from Juno any or all of the inventory of Products held by Juno as of the date of termination. 
  

[***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 32 

 10.5.6 If (x) this Agreement is terminated by Juno pursuant to Section 10.3, and
(y) Opus elects, in its sole discretion, to continue to develop the Products, then Juno will have the option to resume its rights under the terms and conditions set forth in this Agreement. To exercise such option, Juno must (1) deliver
written notice to Opus within the applicable time period specified below (the “Option Period”), and (2) simultaneously pay to Opus the following amounts: 

(a) If such option is exercised prior to the [***], an amount equal to [***]. If such option has not been exercised prior to the [***], then
subject to Juno making an additional payment of [***] to Opus, at least [***] prior to the [***], Juno may extend the Option Period for another [***] period. 

(b) If such option is exercised prior to the [***], an amount equal to [***]. If such option has not been exercised prior to the [***], then
assuming that Juno has made the [***] payment set forth in section 10.5.6(a) above and subject to Juno making an additional payment of [***] to Opus at least [***] prior to the [***], Juno may extend the Option Period for another [***] period; or

 (c) Subject to the applicable extension payments being made, if such option is exercised prior to the [***], an amount equal to [***].
For the avoidance of doubt, in no event shall the Option Period be extended [***]. 
 If such option is exercised, the termination of this Agreement will be
deemed rescinded, and this Agreement will continue as if it had never terminated. At any time during the Option Period, upon Juno’s request, Opus will provide Juno with a statement of [***] incurred by Opus during such period. On a [***] basis
prior to the expiration of the Option Period, Opus shall prepare and deliver to Juno a written summary report that shall describe (a) the progress of the development, and testing of Products in clinical trials, and (b) the status of
obtaining Registrations for the Products; and Opus will permit Juno to have access to any data generated by or on behalf of Opus in testing Product in clinical trials, as such data becomes available to Opus. All of information and data provided by
Opus to Juno under this Section 10.5.6 will be deemed Confidential Information of Opus and subject to the confidentiality obligations of Article 8; provided that, notwithstanding the term set forth in Section 8.1, the obligations of
confidentiality under Section 8.1 will continue during the Option Period and for a period of [***] after expiration of the Option Period. Until the expiration of the Option Period, Opus will not sell, transfer or license any of the rights to
the Licensed IP Rights or Product. 
  
 [***] CERTAIN INFORMATION IN THIS DOCUMENT
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 33 

 11. INDEMNIFICATION 

11.1 Indemnification. 
 11.1.1
Subject to Section 11.2, Juno shall defend, indemnify and hold Opus, its Affiliates, the NIH, and their respective officers, directors, employees, and agents harmless from all losses, liabilities, damages and expenses (including attorneys’
fees and costs, collectively, “Losses”) incurred as a result of any claim, demand, action or proceeding, in each case brought by a Third Party arising out of [***]. 

11.2 Procedure. The party seeking indemnification (the “Indemnitee”) promptly shall notify the other party (the
“Indemnitor”) of any liability or action in respect of which the Indemnitee intends to claim such indemnification; provided that a failure to provide such notice promptly shall not relieve the Indemnitor of any liability to the Indemnitee
except to the extent the Indemnitor is actually prejudiced thereby. The Indemnitor shall have the right to assume the defense thereof with counsel selected by the Indemnitor and reasonably acceptable to the Indemnitee, provided that in the event
Juno is recovering Losses through an offset against payments owing to Opus under Section 4, Juno shall have the right to control the defense with counsel selected by Juno. The indemnity agreement in this Section 11 shall not apply to
amounts paid in settlement of any Losses if such settlement is effected without the consent of the Indemnitor, which consent shall not be withheld unreasonably. The Indemnitee under this Section 11, its employees and agents shall reasonably
cooperate with the Indemnitor and its legal representatives in the investigation and defense of any action, claim or liability covered by this indemnification. 

11.3 Insurance. Juno shall maintain adequate liability insurance (including product liability insurance) with respect to the research,
development, manufacture and sales of Products by Juno in such amount as are customary in the U.S. biopharmaceutical industry with respect to the research, development, manufacture and sales of its similar products. Juno shall maintain such
insurance for so long as it continues to research, develop, manufacture or sell any Products, and thereafter for so long as it is customary in the industry for a company to maintain insurance covering the research, development, manufacture or sale
of similar products; provided that Juno will maintain insurance in amounts and for periods that is at least equal to what Juno customarily maintains for its similar products. 

11.4 Disclaimer. EXCEPT WITH RESPECT TO [***], TO THE MAXIMUM EXTENT PERMITTED UNDER APPLICABLE LAW, IN NO EVENT WILL EITHER PARTY OR
ITS AFFILIATES OR ITS OR THEIR OFFICERS, DIRECTORS, 
  
 [***] CERTAIN INFORMATION IN
THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  
 34 

 
EMPLOYEES, OR AGENTS BE LIABLE TO THE OTHER PARTY OR ITS AFFILIATES UNDER ANY LEGAL THEORY (INCLUDING CONTRACT, NEGLIGENCE, STRICT LIABILITY IN TORT, OR WARRANTY OF ANY KIND) FOR ANY INDIRECT,
CONSEQUENTIAL, EXEMPLARY, SPECIAL, OR PUNITIVE DAMAGES ARISING FROM OR RELATED TO THIS AGREEMENT, EVEN IF SUCH PARTY KNEW OR SHOULD HAVE KNOWN OF THE POSSIBILITY OF, OR COULD REASONABLY HAVE PREVENTED, SUCH DAMAGES. 

12. FORCE MAJEURE 
 If
either party hereto is prevented from or delayed in the performance of any of its obligations hereunder by reason of acts of God, war, strikes, riots, storms, fires, earthquake, power shortage or failure, failure of the transportation system, or any
other cause whatsoever beyond the reasonable control of the party (“Force Majeure Event”), the party so prevented or delayed shall be excused from the performance of any such obligation during a period that is reasonable in light of
the Force Majeure Event, but no less than the duration of the Force Majeure Event itself; provided that the nonperforming party must promptly notify the other party and take reasonable and diligent efforts to remove the condition causing the Force
Majeure Event; provided further that, if the suspension of performance continues for one hundred and eighty (180) days, and such failure to perform would constitute a breach of any material provision of this Agreement in the absence of such
Force Majeure Event, the non-affected party may terminate this Agreement immediately by written notice to the affected Party. 
 13.
MISCELLANEOUS 
 13.1 Governing Law. This Agreement shall be governed by, interpreted and enforced in accordance with the laws
of the State of New York, without regard to principles of conflicts of laws that would result in the application of the law of any jurisdiction other than New York. All disputes arising out of this Agreement shall be subject to the exclusive
jurisdiction and venue of the state and federal courts located in New York, New York (and the appellate courts thereof), and each party hereby irrevocably consents to the personal and non-exclusive jurisdiction and venue thereof and waives any
objection on the grounds of lack of jurisdiction (including venue) to the exercise of such jurisdiction over it by any such courts. 
 13.2
Independent Contractors. The relationship of the parties under this Agreement is that of independent contractors. Neither party shall be deemed to be an employee, agent, partner, franchisor, franchisee, joint venture or legal representative
of the other for any purpose as a result of this Agreement or the transactions contemplated thereby, and neither shall have the right, power or authority to create any obligation or responsibility on behalf of the other. 

13.3 Assignment. Neither this Agreement nor the rights and obligations under this Agreement shall be delegated, assigned or otherwise
transferred by a party (in whole or part, whether voluntarily or by operation of law, including by way of sale of assets, merger or consolidation) without prior written consent of the other party. Notwithstanding the foregoing, a party may, without
such consent, assign this Agreement and its rights and 

  
 35 

 
obligations hereunder in their entirety (a) to an Affiliate (provided that such party shall remain bound by the terms and conditions hereof), or (b) in connection with a Change of
Control; provided that (i) the assigning party must provide the other party with written notice of such assignment promptly after the effectiveness of such assignment, and (ii) the assignee must in writing to be legally bound by this
Agreement to the same extent as the assigning party and provide the other party with a copy of such assignee undertaking; provided, however, that, as it relates to the rights to receive the Juno Shares, (i) such assignment or transfer must be
in compliance with all applicable federal and state securities laws and (ii)(A) Opus shall have furnished Juno with a detailed description of the manner and circumstances of the proposed disposition, (B) the assignee or transferee shall have
confirmed to the satisfaction of Juno in writing, that the rights with respect to the Applicable Equity Milestone Shares are being acquired (x) solely for the assignee’s or transferee’s own account and not as a nominee for any other
party, (y) for investment and (z) not with a view toward distribution or resale, and (C) Opus and/or the assignee or transferee shall have confirmed such other matters related thereto as may be reasonably requested by Juno.
Notwithstanding the foregoing, Opus may, without such consent, assign its rights to receive payments of consideration other than Juno Shares hereunder. If an Affiliate to whom this Agreement has been assigned by a party ceases to be an Affiliate of
such party, the Affiliate and such party must cause this Agreement to be assigned back to such party, which obligation must be a condition included in the original assignment. Subject to the foregoing, this Agreement shall be binding on and inure to
the benefit of the parties and their permitted successors and assigns. Any attempted delegation, assignment or transfer in violation of the foregoing shall be null and void. 

13.4 Right to Develop Independently. Nothing in this Agreement shall impair Juno’s right to independently acquire, license,
develop for itself, or have others develop for it, intellectual property and technology performing similar functions as the Licensed IP Rights and/or Technology or to market and distribute products or services based on such other intellectual
property and technology. 
 13.5 Bankruptcy. The licenses and sublicenses granted by Opus under this Agreement are and shall be
deemed to be, for purposes of 11 U.S.C. Section 365(n), a license of “Intellectual Property Rights” as defined thereunder, and if Opus is under any proceeding under the United States Bankruptcy Code and the trustee in bankruptcy of
Opus, or Opus as a debtor in possession, elects to reject the foregoing license, Juno may, pursuant to 11 U.S.C. Section 365(n)(1) and (2), retain any and all of Juno’s rights under such license and sublicense to the maximum extent
permitted by law. 
 13.6 Notices. Any notices required or permitted under this Agreement or required by law must be in writing by
international express delivery service (such as DHL or Federal Express), in each case properly posted and fully prepaid to the applicable address below, or to such other address as either party may substitute by written notice under this
Section 13.6. Notice shall be deemed to have been given when delivered. 

  
 36 

							
		  	If to Opus:	 	Opus Bio, Inc.	  	
		  		 	537 Steamboat Road	  	
		  		 	Suite 200	  	
		  		 	Greenwich, CT 06830	  	
		  		 	Attention: Chief Executive Officer

  

							
		  	If to Juno:	 	Juno Therapeutics, Inc.	  	
		  		 	307 Westlake Avenue North, Suite 300	  	
		  		 	Seattle, Washington, 98109, USA	  	
		  		 	Attention: General Counsel	  	

 13.7 Interpretation. The captions and headings to this Agreement are for convenience only, and are to
be of no force or effect in construing or interpreting any of the provisions of this Agreement. Unless specified to the contrary, references to Articles, Sections or Exhibits mean the particular Articles, Sections or Exhibits to this Agreement and
references to this Agreement include all Exhibits hereto. Unless context otherwise clearly requires, whenever used in this Agreement: (a) the words “include” or “including” shall be construed as incorporating, also,
“but not limited to” or “without limitation;” (b) the word “day” or “year” means a calendar day or year unless otherwise specified; (c) the word “notice” shall mean notice in writing
(whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement; (d) the words “hereof,” “herein,” “hereby” and derivative or
similar words refer to this Agreement (including any Exhibits); (e) the word “or” shall be construed as the inclusive meaning identified with the phrase “and/or;” (f) provisions that require that a party, the parties
hereunder “agree,” “consent” or “approve” or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter or otherwise; (g) words of any gender
include the other gender; (h) words using the singular or plural number also include the plural or singular number, respectively; (i) the word “law” (or “laws”) when used herein means any applicable, legally binding
statute, ordinance, resolution, regulation, code, guideline, rule, order, decree, judgment, injunction, mandate or other legally binding requirement of a government entity, together with any then-current modification, amendment and re-enactment
thereof, and any legislative provision substituted therefor; and (j) the word “will” shall be construed to have the same meaning and effect as the word “shall.” The parties and their respective counsel have had an
opportunity to fully negotiate this Agreement. If any ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or
disfavoring any party by virtue of the authorship of any provision of this Agreement. No prior draft of this Agreement shall be used in the interpretation or construction of this Agreement. 

13.8 Further Assurances. At any time or from time to time on and after the date of this Agreement, each party shall at the written
request of the other party: (a) deliver to the other party such records, data or other documents consistent with the provisions of this Agreement; (b) execute, and deliver or cause to be delivered, all such consents, documents or further
instruments of transfer or license; and (c) take or cause to be taken all such actions, as the other party may reasonably deem necessary or desirable in order for the other party to obtain the full benefits of this Agreement and the
transactions contemplated hereby. 

  
 37 

 13.9 Use of Names and Marks. Neither party shall use the name, trade name, trademark or
other designation of the other party or its employees in connection with any products, promotion or advertising without the prior written permission of the other party. 

13.10 Severability. If any provision, or portion thereof, in this Agreement is held to be invalid or unenforceable to any extent, such
provision of this Agreement shall be enforced to the maximum extent permissible by applicable law so as to effect the intent of the Parties, and the remainder of the Agreement shall remain in full force and effect. The Parties shall negotiate in
good faith a valid and enforceable substitute provision for any invalid or unenforceable provision that most nearly achieves the intent and economic effect of such invalid or unenforceable provision as if it were enforceable. 

13.11 Waiver. Any waiver of any provision of this Agreement or of a party’s rights or remedies under this Agreement must be in
writing to be effective. Failure, neglect, or delay by a party to enforce the provisions of this Agreement or its rights or remedies at any time, shall not be construed as a waiver of such party’s rights under this Agreement and shall not in
any way affect the validity of the whole or any part of this Agreement or prejudice such party’s right to take subsequent action. No exercise or enforcement by either party of any right or remedy under this Agreement shall preclude the
enforcement by such party of any other right or remedy under this Agreement or that such party is entitled by law to enforce. 
 13.12
Entire Agreement; Modification. This Agreement (including the Exhibits, the Confidential Disclosure Agreement between the parties dated September 4, 2014, and any amendments hereto or thereto signed by both parties) constitutes the
entire understanding and agreement between the parties with respect to the subject matter hereof and supersedes any and all prior and contemporaneous negotiations, representations, agreements, and understandings, written or oral, that the parties
may have reached with respect to the subject matter hereof. Except as set forth in Section 13.10, this Agreement may not be altered, amended or modified in any way except by a writing (excluding email or similar electronic transmissions) signed
by the authorized representatives of both parties. 
 13.13 Counterparts. This Agreement may be executed in two or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile and other electronically scanned signatures shall have the same effect as their originals. 

13.14 Export Control. Juno acknowledges that it is subject to and agrees to abide by the United States laws and regulations (including
the Export Administration Act of 1979 and Arms Export Control Act) controlling the export of technical data, computer software, laboratory prototypes, biological material, and other commodities. The transfer of these items may require a license from
the appropriate agency of the U.S. Government or written assurances by Juno that it shall not export these items to certain foreign countries without prior approval of such agency. 

  
 38 

 IN WITNESS WHEREOF, the parties hereto have caused their duly authorized representatives to
execute this Agreement as of the Execution Date. 
  

			
	OPUS BIO, INC.
		
	By:	 	             /s/ Douglas D. Lind

		
	Name:	 	             Douglas D. Lind

		
	Title	 	             Interim CEO

	
	JUNO THERAPEUTICS, INC.
		
	By:	 	             /s/ Hans Bishop

		
	Name:	 	             Hans Bishop

		
	Title	 	             CEO

  
 39 

 EXECUTION VERSION 

EXHIBIT A 
 LICENSED PATENT
RIGHTS 
 [***] 
  

[***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

  

 EXHIBIT B 

OPUS IN-LICENSES TERMS 
  

	5.	STATUTORY AND NIH REQUIREMENTS AND RESERVED GOVERNMENT RIGHTS 

  

	  	5.1 	(a)	 The NIH reserves on behalf of the Government an irrevocable, nonexclusive, nontransferable, royalty-free license for the
practice of all inventions licensed under the Licensed Patent Rights throughout the world by or on behalf of the Government and on behalf of any foreign government or international organization pursuant to any existing or future treaty
or agreement to which the Government is a signatory. Prior to the First Commercial Sale, the Licensee agrees to provide the NIH with reasonable quantities of the Licensed Products or materials made through the
Licensed Processes for NIH research use; and 

  

	 	(b)	In the event that the Licensed Patent Rights are Subject Inventions made under CRADA, the Licensee grants to the Government, pursuant to 15 U.S.C. § 3710a(b)(l)(A), a
nonexclusive, nontransferable, irrevocable, paid-up license to practice the Licensed Patent Rights or have the Licensed Patent Rights practiced throughout the world by or on behalf of the Government. In the exercise of this
license, the Government shall not publicly disclose trade secrets or commercial or financial information that is privileged or confidential within the meaning of 5 U.S.C. § 552(b)(4) or which would be considered as such if it had
been obtained from a non-Federal party. Prior to the First Commercial Sale, the Licensee agrees to provide the NIH with reasonable quantities of the Licensed Products or materials made through the Licensed
Processes for NIH research use. 

  

	 	(c)	Prior to the First Commercial Sale, Licensee agrees to provide NIH with reasonable quantities of Licensed Products or materials made through the Licensed Processes for NIH
research use, provided that NIH shall not provide such Licensed Products or materials to any Third Party. The determination of the quantities to be provided shall be determined based on discussions between Licensee and
NIH (initially Dr. Boro Dropulic and Dr. Crystal Mackall). The obligation shall terminate upon First Commercial Sale of any Licensed Product. The Licensed Products shall not be used in humans or in toxicology
experiments in animals unless agreed in writing between authorized representatives of both Licensee and the NIH. 

  

	 	5.2	The Licensee agrees that products used or sold in the United States embodying the Licensed Products or produced through use of the Licensed Processes shall be manufactured substantially in the
United States, unless a written waiver is obtained in advance from the NIH. 

  

	 	5.3	The Licensee acknowledges that the NIH may enter into future CRADAs under the Federal Technology Transfer Act of 1986 that relate to the subject matter of this Agreement. The
Licensee agrees not to unreasonably deny requests for a Research 

	 	
License from future collaborators with the NIH when acquiring these rights is necessary in order to make a CRADA project feasible. The Licensee may request an
opportunity to join as a party to the proposed CRADA. 

  

	  	5.4 	(a)	 in addition to the reserved license of Paragraph 5.1, the NIH reserves the right to grant Research Licenses directly or to
require the Licensee to grant Research Licenses on reasonable terms. The purpose of these Research Licenses is to encourage basic research, whether conducted at an academic or corporate facility. In order to safeguard the
Licensed Patent Rights, however, the NIH shall consult with the Licensee before granting to commercial entities a Research License or providing to them research samples of materials made through the Licensed
Processes; and 

  

	 	(b)	in exceptional circumstances, and in the event that the Licensed Patent Rights are Subject Inventions made under a CRADA, the Government, pursuant to 15 U.S.C. § 3710a(b)(1)(B), retains
the right to require the Licensee to grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive sublicense to use the Licensed Patent Rights in the Licensed Field of Use on terms that are reasonable under
the circumstances, or if the Licensee fails to grant this license, the Government retains the right to grant the license itself. The exercise of these rights by the Government shall only be in exceptional circumstances and only
if the Government determines: 

  

	 	(i)	the action is necessary to meet health or safety needs that are not reasonably satisfied by the Licensee; 

  

	 	(ii)	the action is necessary to meet requirements for public use specified by Federal regulations, and these requirements are not reasonably satisfied by the Licensee; or 

 

	 	(iii)	the Licensee has failed to comply with an agreement containing provisions described in 15 U.S.C. § 3710a(c)(4)(B); and 

  

	 	(c)	the determination made by the Government under this Paragraph 5.4 is subject to administrative appeal and judicial review under 35 U.S.C. § 203(b). 

 

	8.	RECORD KEEPING 

  

	 	8.1	 The Licensee agrees to keep accurate and correct records of the Licensed Products made, used, sold, or imported and the Licensed
Processes practiced under this Agreement appropriate to determine the amount of royalties due the NIH. These records shall be retained for at least five (5) years following a given reporting period and shall be available
during normal business hours for inspection, at the expense of the NIH, by an accountant or other designated auditor selected by the NIH for the sole purpose of verifying reports and royalty payments hereunder. The accountant or
auditor shall only disclose to the NIH information relating to the 

	 	
accuracy of reports and royalty payments made under this Agreement. If an inspection shows an underreporting or underpayment in excess of five percent (5%) for any twelve
(12) month period, then the Licensee shall reimburse the NIH for the cost of the inspection at the time the Licensee pays the unreported royalties, including any additional royalties as required by Paragraph 9.8. All
royalty payments required under this Paragraph shall be due within sixty (60) days of the date the NIH provides to the Licensee notice of the payment due. 

 

	10.	PERFORMANCE 

  

	 	10.1	The Licensee shall use its reasonable commercial efforts to bring the Licensed Products and the Licensed Processes to Practical Application. “Reasonable commercial efforts” for the
purposes of this provision shall include adherence to the Commercial Development Plan in Appendix E and performance of the Benchmarks in Appendix D. The efforts of a sublicensee shall be considered the efforts of the Licensee.

  

	 	10.2	Upon the First Commercial Sale, until the expiration or termination of this Agreement, the Licensee shall use its reasonable commercial efforts to make the Licensed Products and the
Licensed Processes reasonably accessible to the United States public. 

  

	12.	NEGATION OF WARRANTIES AND INDEMNIFICATION 

  

	 	12.5	The Licensee shall indemnify and hold the NIH, its employees, students, fellows, agents, and consultants harmless from and against all liability, demands, damages, expenses, and losses, including but not
limited to death, personal injury, illness, or property damage in connection with or arising out of: 

  

	 	(a)	the use by or on behalf of the Licensee, its sublicensees, directors, employees, or third parties of any Licensed Patent Rights; or 

 

	 	(b)	the design, manufacture, distribution, or use of any Licensed Products, Licensed Processes or materials by the Licensee, or other products or processes developed in connection with or arising out of
the Licensed Patent Rights. 

  

	13.	TERM, TERMINATION, AND MODIFICATION OF RIGHTS 

  

	 	13.8	The NIH reserves the right according to 35 U.S.C. § 209(d)(3) to terminate or modify this Agreement if it is determined that this action is necessary to meet the requirements for public use
specified by federal regulations issued after the date of the license and these requirements are not reasonably satisfied by the Licensee. 

	 	13.9	Within thirty (30) days of receipt of written notice of the NIH’s unilateral decision to modify or terminate this Agreement, the Licensee may, consistent with the provisions of 37
C.F.R. § 404.11, appeal the decision by written submission to the designated NIH official. The decision of the designated the NIH official shall be the final agency decision. The Licensee may thereafter exercise any and
all administrative or judicial remedies that may be accessible. 

  

	 	13.10	Within ninety (90) days of expiration or termination of this Agreement under this Article 13, a final report shall be submitted by the Licensee. Any royalty payments, including those incurred but not
yet paid (such as the full minimum annual royalty), and those related to patent expenses, due to the NIH shall become immediately due and payable upon termination or expiration. If terminated under this Article 13, sublicensees may elect to
convert their sublicenses to direct licenses with the NIH pursuant to Paragraph 4.3. Unless otherwise specifically provided for under this Agreement, upon termination or expiration of this Agreement, the Licensee shall
return all Licensed Products or other materials included within the Licensed Patent Rights to the NIH or provide the NIH with certification of the destruction thereof. The Licensee may not be granted additional
NIH licenses if the final reporting requirement is not fulfilled. 

 EXHIBIT C 

SERIES B STOCK PURCHASE AGREEMENT 

[ATTACHED] 

  
  

JUNO THERAPEUTICS, INC. 

STOCK PURCHASE AGREEMENT 

December 3, 2014 

 TABLE OF CONTENTS 

 

									
	 	 	 	  	 	  	Page	 
	Section 1 Authorization, Sale and Issuance	  	 	1	  
		 	1.1	  	Authorization	  	 	1	 
		 	1.2	  	Purchase and Sale of Shares	  	 	1	 
	Section 2 Closing Date and Delivery	  	 	2	  
		 	2.1	  	Closing; Delivery	  	 	2	 
		 	2.2	  	The Agreements	  	 	2	 
	 Section 3 Representations and Warranties of the Company
	  	 	2	 
		 	3.1	  	Organization, Good Standing and Qualification	  	 	2	 
		 	3.2	  	Subsidiaries	  	 	2	  
		 	3.3	  	Capitalization	  	 	3	 
		 	3.4	  	Authorization	  	 	3	 
		 	3.5	  	Financial Statements	  	 	4	 
		 	3.6	  	Changes	  	 	4	 
		 	3.7	  	Material Contracts	  	 	4	 
		 	3.8	  	Intellectual Property	  	 	4	  
		 	3.9	  	Governmental Consent	  	 	5	 
		 	3.10	  	Title to Properties and Assets; Liens	  	 	5	 
		 	3.11	  	Compliance with Other Instruments	  	 	5	  
		 	3.12	  	Offering	  	 	5	  
		 	3.13	  	No “Bad Actor” Disqualification	  	 	6	  
		 	3.14	  	Registration Rights	  	 	6	 
		 	3.15	  	Brokers or Finders	  	 	6	 
		 	3.16	  	Investment Company	  	 	6	 
	Section 4 Representations and Warranties of Opus	  	 	6	 
		 	4.1	  	No Registration	  	 	6	 
		 	4.2	  	Investment Intent	  	 	6	 
		 	4.3	  	Investment Experience	  	 	7	 
		 	4.4	  	Speculative Nature of Investment	  	 	7	  
		 	4.5	  	Access to Data	  	 	7	 
		 	4.6	  	Accredited Investor	  	 	7	 
		 	4.7	  	Rule 144	  	 	8	  
		 	4.8	  	No Public Market	  	 	8	 
		 	4.9	  	Authorization	  	 	8	 
		 	4.10	  	Brokers or Finders	  	 	9	  
		 	4.11	  	Tax Advisors	  	 	9	  
		 	4.12	  	Legends	  	 	9	  
		 	4.13	  	No “Bad Actor” Disqualification Events	  	 	9	  
	Section 5 Conditions to Opus’ Obligations to Close	  	 	10	 
		 	5.1	  	Conditions to Closing	  	 	10	 
	Section 6 Conditions to Company’s Obligation to Close	  	 	10	 
		 	6.1	  	Representations and Warranties	  	 	10	  
		 	6.2	  	Covenants	  	 	10	  
		 	6.3	  	Compliance with Securities Laws	  	 	11	  

  
 -i- 

 TABLE OF CONTENTS 

(continued) 
  

									
	 	 	 	  	 	  	Page	 
		 	6.4	  	Consents and Waivers	  	 	11	  
	Section 7 Miscellaneous	  	 	11	 
		 	7.1	  	Amendment	  	 	11	 
		 	7.2	  	Notices	  	 	11	 
		 	7.3	  	Governing Law	  	 	12	 
		 	7.4	  	Brokers or Finders	  	 	12	 
		 	7.5	  	Expenses	  	 	12	 
		 	7.6	  	Survival	  	 	12	 
		 	7.7	  	Successors and Assigns	  	 	12	 
		 	7.8	  	Entire Agreement	  	 	13	 
		 	7.9	  	Delays or Omissions	  	 	13	 
		 	7.10	  	California Corporate Securities Law	  	 	13	 
		 	7.11	  	Severability	  	 	13	 
		 	7.12	  	Counterparts	  	 	13	  
		 	7.13	  	Telecopy Execution and Delivery	  	 	13	  
		 	7.14	  	Jurisdiction; Venue	  	 	14	 
		 	7.15	  	Further Assurances	  	 	14	 
		 	7.16	  	Attorney’s Fees	  	 	14	 
		 	7.17	  	Jury Trial	  	 	14	 
		 	7.18	  	Waiver of Potential Conflicts of Interest	  	 	14	 

  
 -ii- 

 EXHIBITS 
  

			
	 A
	  	Exclusive License Agreement
		
	 B
	  	Amended and Restated Certificate of Incorporation
		
	 C
	  	Fourth Amended and Restated Investors’ Rights Agreement
		
	 D
	  	Schedule of Exceptions
		
	 E
	  	Compliance Certificate
		
	 F
	  	Market Stand-Off Agreement

  
 -iii- 

 JUNO THERAPEUTICS, INC. 

STOCK PURCHASE AGREEMENT 
 This Stock
Purchase Agreement (this “Agreement”) is dated as of December 3, 2014, and is between Juno Therapeutics, Inc., a Delaware corporation (the “Company”), and Opus Bio, Inc., a Delaware corporation
(“Opus”), having a place of business at 537 Steamboat Road, Suite 200, Greenwich, CT 06830. 
 WHEREAS, Opus and the Company are
entering into this Agreement, providing for, among other things, the purchase and sale of capital stock of the Company in connection with Opus’ grant of rights and licenses to the Company pursuant to an Exclusive License Agreement, by and
between the Company and Opus, dated as of the date hereof (a copy of which is attached hereto as Exhibit A) (the “License Agreement”). 

NOW, THEREFORE, in consideration of the covenants, representations, warranties and mutual agreements hereinafter set forth, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties hereto agree as follows: 

SECTION 1 

Authorization, Sale and Issuance 

1.1 Authorization. The Company will, prior to the Closing (as defined below), authorize (a) the sale and issuance of
(i) 6,410,256 shares (the “Shares”) of the Company’s capital stock and (b) if applicable, the reservation of 2,747,253 shares of Common Stock for issuance upon conversion of a portion of the Shares (the
“Conversion Shares”). 
 1.2 Purchase and Sale of Shares. Subject to the terms and conditions of this
Agreement and Section 4.2 of the License Agreement, Opus agrees to purchase, and the Company agrees to sell and issue to Opus, (i) if the Closing (as defined below) occurs prior to the date on which the Company consummates its
initial public offering of its Common Stock, 2,747,253 shares of the Company’s Series B Preferred Stock, par value $0.0001 per share (the “Series B Preferred”), having the rights, privileges, preferences and
restrictions set forth in the third amended and restated certificate of incorporation of the Company, in substantially the form of Exhibit B (the “Restated Certificate”) and 3,663,003 shares of common stock of the
Company, par value $0.0001 per share (“Common Stock”) and (ii) if the Closing occurs on or after the date on which the Company has consummated its initial public offering of Common Stock, 6,410,256 shares of Common
Stock. As full consideration for the Company’s agreement to sell and issue the Shares, Opus has granted certain rights and licenses to the Company pursuant to the License Agreement. The parties agree and acknowledge that the Company
is contemplating an amendment to the Restated Certificate to effect a reverse split of its Common Stock and Preferred Stock (the “Reverse Split”). If the Closing occurs after the effectiveness of the Reverse Split, the number
of shares of Series B Preferred or Common Stock, as applicable, issued in Closing shall be adjusted in accordance with the Reverse Split. For example, if the Reverse Split combines each four shares of Common Stock and each series of Preferred Stock
into one share of Common Stock and each series of Preferred Stock, respectively, then the aggregate number of shares of Series B Preferred and/or Common Stock, as applicable, to be issued in the Closing would be 1,602,564. 

  
 1 

 SECTION 2 

Closing Date and Delivery 

2.1 Closing; Delivery. The purchase and sale of the Shares shall take place remotely via the exchange of documents and signatures,
at 10:00 a.m., on the Effective Date (as defined in the License Agreement) or at such other time as the Company and Opus mutually agree upon, orally or in writing (the “Closing”). Promptly following the Closing, the Company
shall deliver a certificate or certificates, as the case may be, registered in the name of Opus representing the number of Shares being issued. 

2.2 The Agreements. Upon execution and delivery of the relevant signature pages at the Closing, Opus shall become party to, and be
bound by, the Fourth Amended and Restated Investors’ Rights Agreement in substantially the form attached hereto as Exhibit C (the “Rights Agreement” and together with this Agreement, the
“Agreements”). 
 SECTION 3 

Representations and Warranties of the Company 

A Schedule of Exceptions, attached as Exhibit D (each, a “Schedule of Exceptions”) shall be delivered to Opus in
connection with the Closing. The Schedule of Exceptions shall be arranged in sections corresponding to the numbered sections and lettered subsections contained in this Section 3. Any disclosure set forth in any particular section and
subsection of the Schedule of Exceptions will be deemed disclosed for any other section and subsection of the Schedule of Exceptions to the extent that its relevance or applicability to such other Section of the Schedule of Exceptions is reasonably
apparent on its face upon a reading of the disclosure without any independent knowledge on the part of the reader regarding the matter disclosed and without reference to any underlying agreement or other document. Except as set forth on the Schedule
of Exceptions delivered to Opus at the Closing, the Company hereby represents and warrants to Opus as of the date of this Agreement as follows: 

3.1 Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good
standing under the laws of the State of Delaware. The Company has the requisite corporate power and authority to own and operate its properties and assets, to carry on its business as presently conducted or proposed to be conducted, to execute and
deliver the Agreements, to issue and sell the Shares and, if applicable, the Conversion Shares and to perform its obligations pursuant to each of the Agreements and the Company’s certificate of incorporation in effect as of the time of such
Closing. The Company is presently qualified to do business and is in good standing as a foreign corporation in each jurisdiction where the failure to be so qualified could reasonably be expected to have a material adverse effect on the
Company’s financial condition or business as now conducted or proposed to be conducted (a “Material Adverse Effect”). 

3.2 Subsidiaries. The Company does not own or control, directly or indirectly, any majority interest in any corporation,
partnership, limited liability company, association, or other business entity. 

  
 2 

 3.3 Capitalization. 

(a) Immediately prior to the Closing, the authorized capital stock of the Company will consist of 400,000,000 shares of Common Stock, of which
64,952,200 shares are issued and outstanding, 243,658,977 shares of Preferred Stock authorized, 87,722,673 of which are designated Series A Preferred, all of which are issued and outstanding, 9,000,000 of which are designated Series A-1
Preferred Stock, all of which are issued and outstanding, 93,936,304 shares of Series A-2 Preferred Stock, all of which are issued and outstanding and 53,000,000 shares of Series B Preferred stock, 48,978,730 of which are issued and outstanding. As
of the date of this Agreement, the Common Stock, Series A Preferred, Series A-1 Preferred, Series A-2 Preferred and Series B Preferred have the rights, preferences, privileges and restrictions set forth in the Restated Certificate. 

(b) The outstanding shares have been duly authorized and validly issued in compliance with applicable laws, and are fully paid and
nonassessable. As of the date of this Agreement, the Company has a right of first refusal over transfers of all outstanding shares of Common Stock. 

(c) As of the date of this Agreement, the Company has not reserved securities for issuance, except as set forth below: 

(i) the Shares for issuance pursuant to this Agreement; 

(ii) shares of Common Stock (as may be adjusted in accordance with the provisions of the Restated Certificate) for issuance upon conversion
of a portion of the Shares (if applicable) and the other issued and outstanding shares of Preferred Stock; and 
 (iii)
55,658,147 shares of Common Stock authorized for issuance to employees, consultants and directors pursuant to its 2013 Equity Incentive Plan, under which (A) options to purchase 10,740,908 shares are issued and outstanding as of the date
of this Agreement and (B) restricted stock awards with respect to which 43,110,551 shares are issued and outstanding. All such outstanding shares have been issued in compliance with state and federal securities laws. 

(d) The Shares, when issued and delivered and paid for in compliance with the provisions of this Agreement, will be validly issued, fully paid
and nonassessable. The Conversion Shares have been duly and validly reserved and, if and when issued in compliance with the provisions of this Agreement, the Restated Certificate and applicable law, will be validly issued, fully paid and
nonassessable. The Shares and, if applicable, the Conversion Shares will be free of any liens or encumbrances, other than any liens or encumbrances created by or imposed upon Opus; provided, however, that the Shares and, if applicable, the
Conversion Shares are subject to restrictions on transfer under U.S. state and/or federal securities laws and as set forth herein and in the Rights Agreement. Except as set forth in the Rights Agreement, the Shares and, if applicable, the Conversion
Shares are not subject to any preemptive rights or rights of first refusal. 
 3.4 Authorization. All corporate action on the
part of the Company and its directors, officers and stockholders necessary for the authorization, execution and delivery of the Agreements by the Company, the authorization, sale, issuance and delivery of the Shares and the Conversion Shares, and
the performance of all of the Company’s obligations under the Agreements has been taken or will be taken prior to the Closing. The Agreements, when executed and delivered by the Company, shall 

  
 3 

 
constitute valid and binding obligations of the Company, enforceable in accordance with their terms, except (i) as limited by laws of general application relating to bankruptcy, insolvency
and the relief of debtors, (ii) as limited by rules of law governing specific performance, injunctive relief or other equitable remedies and by general principles of equity, and (iii) to the extent the indemnification provisions contained
in the Rights Agreement may further be limited by applicable laws and principles of public policy. 
 3.5 Financial
Statements. The Company has delivered or made available to Opus: (i) its audited balance sheet, cash flow statement and statement of operations for the period from inception through December 31, 2013, and (ii) its unaudited
balance sheet, cash flow statement and statement of operations for the nine months ended September 30, 2014 (such date, the “Balance Sheet Date” and such statements, collectively, the “Financial
Statements”). The Financial Statements are correct in all material respects and present fairly the financial condition and operating results of the Company as of the date(s) and during the period(s) indicated therein, subject in the
case of the unaudited Financial Statements to normal year-end audit adjustments. The Financial Statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) applied on a consistent basis
throughout the period indicated, except as disclosed therein. 
 3.6 Changes. To the Company’s knowledge, since the Balance
Sheet Date, there has not been any event or condition of any type that has had a Material Adverse Effect. 
 3.7 Material
Contracts. Set forth in Section 3.7 of the Schedule of Exceptions is a list as of the Closing of any and all contracts, instruments, agreements and understandings with respect to the Company that it believes would be required to be
filed as an exhibit to a registration statement on Form S-1 pursuant to Item 601(b)(4), (b)(10)(i) or (b)(10)(ii) (collectively the “Material Contracts”) under Regulation S-K promulgated under the Securities Act of 1933,
as amended (the “Securities Act”) if the Company was the registrant under the Securities Act as of the date hereof. Except as disclosed in Section 3.7 of the Schedule of Exceptions, each Material Contract is in full
force and effect and is a legal, valid and binding contract or agreement of the Company, and after giving effect to the consummation of the transactions contemplated by this Agreement, there will be no material default (or any event which, with the
giving of notice or lapse of time or both, would be a material default) by the Company or, to the knowledge of the Company, in the timely performance of any obligation to be performed or paid under any of the Material Contracts, in each case, that
would result in a Material Adverse Effect. No written notice has been received by the Company of any material default under or termination of any Material Contract which has not been cured or waived as of the date hereof. 

3.8 Intellectual Property. As used herein, the term “Intellectual Property” means all patents, patent
applications, trademarks, trademark applications, service marks, trade names, copyrights, trade secrets, licenses, domain names, mask works, information and proprietary rights and processes, anywhere in the world. To the knowledge of the Company
(without having conducted any special investigation or patent search), the Company owns, has license rights to or possesses or can obtain on commercially reasonable terms sufficient legal rights to all Intellectual Property necessary to the business
of the Company as presently conducted and as presently proposed to be conducted, the lack of which could reasonably be expected to have a Material Adverse Effect. The Company has not received any written communication alleging that the Company has
violated any of the Intellectual Property of any other person or entity. None of the Intellectual Property owned or in-licensed by the Company (collectively, “Company Intellectual Property”) is subject to any outstanding
judgment, 

  
 4 

 
decree, order, writ, award, injunction or determination of an arbitrator or court or other governmental authority affecting the rights of the Company with respect thereto. There are no actions
currently pending before any court or government entity contesting the use or ownership of any Company Intellectual Property. The Company has taken reasonable security measures to protect the secrecy, confidentiality and value of all trade secrets,
knowhow and other confidential and proprietary information owned by the Company or used by the Company in the Company’s business as now conducted. To the Company’s knowledge, (i) the Company Intellectual Property was not procured by
fraud, (ii) the Company Intellectual Property has not had title voided because of an improper ownership transfer, and (iii) issued patents within the Company Intellectual Property have not been canceled by any governmental authority
(except for expiration or terminal disclaimers). 
 3.9 Governmental Consent. No consent, approval or authorization of, or
designation, declaration, notification or filing with any governmental authority on the part of the Company is required in connection with the valid execution and delivery of this Agreement, or the offer, sale or issuance of the Shares and, if
applicable, the Conversion Shares, or the consummation of any other transaction contemplated by this Agreement, except (i) the filing of such notices as may be required under the Securities Act and (ii) such filings as may be required
under applicable state securities laws. 
 3.10 Title to Properties and Assets; Liens. The Company has good and marketable title
to its properties and assets, and has good title to all its leasehold interests, in each case subject to no material mortgage, pledge, lien, lease, encumbrance or charge, other than (i) liens for current taxes not yet due and payable,
(ii) liens imposed by law and incurred in the ordinary course of business for obligations not past due, (iii) liens in respect of pledges or deposits under workers’ compensation laws or similar legislation, and (iv) liens,
encumbrances and defects in title which do not in any case materially detract from the value of the property subject thereto or have a Material Adverse Effect. With respect to the property and assets it leases, the Company is in compliance with such
leases in all material respects and, to its knowledge, holds a valid leasehold interest free of any liens, claims or encumbrances, subject to clauses (i)-(iv) above. 

3.11 Compliance with Other Instruments and Laws. The Company is not in violation of any term of its certificate of incorporation
or bylaws, each as amended to date. To the Company’s knowledge, the Company is not in violation of any federal or state statute, rule or regulation applicable to the Company the violation of which would have a Material Adverse Effect. The
execution and delivery of the Agreements by the Company, the performance by the Company of its obligations pursuant to the Agreements, and the issuance of the Shares, and the Conversion Shares, will not result in any violation of the Company’s
certificate of incorporation or bylaws, each as amended to date, or any material violation, or materially conflict with, or constitute a material default under, any of its Material Contracts, nor, to the Company’s knowledge, result in the
creation of any material mortgage, pledge, lien, encumbrance or charge upon any of the properties or assets of the Company. 
 3.12
Offering. Subject to the accuracy of Opus’ representations and warranties in Section 4, the offer, sale and issuance of the Shares to be issued in conformity with the terms of this Agreement and, if applicable, the issuance
of the Conversion Shares, constitute transactions exempt from the registration requirements of Section 5 of the Securities Act and from the registration or qualification requirements of applicable state securities laws, and neither the Company
nor any authorized agent acting on its behalf will take any action hereafter that would cause the loss of such exemption. 

  
 5 

 3.13 No “Bad Actor” Disqualification. The Company has exercised reasonable
care, in accordance with SEC rules and guidance, to determine whether any Covered Person (as defined below) is subject to any of the “bad actor” disqualifications described in Rule 506(d)(1)(i) through (viii) under the Securities
Act (“Disqualification Events”). Neither the Company nor, to the Company’s knowledge, any Covered Person is subject to a Disqualification Event, except for a Disqualification Event covered by Rule 506(d)(2) or
(d)(3) under the Securities Act. The Company has complied, to the extent applicable, with any disclosure obligations under Rule 506(e) under the Securities Act. “Covered Persons” are those persons specified in
Rule 506(d)(1) under the Securities Act, including the Company; any predecessor or affiliate of the Company; any director, officer (as defined under Rule 16a-1, promulgated under the Securities and Exchange Act of 1934, as amended (the
“Exchange Act”)), other officer participating in the offering, general partner or managing member of the Company; any beneficial owner of twenty percent (20%) or more of the Company’s outstanding voting equity
securities, calculated on the basis of voting power; any promoter (as defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of the sale of the Shares; and any person that has been or will be paid
(directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of the Shares (a “Solicitor”), any general partner or managing member of any Solicitor, and any director, officer (as defined
under Rule 16a-1, promulgated under the Exchange Act) or other officer participating in the offering of any Solicitor or general partner or managing member of any Solicitor. 

3.14 Registration Rights. Except as set forth in the Rights Agreement, the Company is presently not under any obligation and has
not granted any rights to register under the Securities Act any of its presently outstanding securities or any of its securities that may hereafter be issued. 

3.15 Brokers or Finders. The Company has not incurred, and will not incur, directly or indirectly, as a result of any action taken
by the Company, any liability for brokerage or finders’ fees or agents’ commissions or any similar charges in connection with this Agreement or any of the transactions contemplated hereby. 

3.16 Investment Company. The Company is not an investment company within the meaning of the Investment Company Act of 1940, as amended.

 SECTION 4 

Representations and Warranties of Opus 

Opus hereby represents and warrants to the Company as follows: 

4.1 No Registration. Opus understands that the Shares and the Conversion Shares, have not been, and will not be, registered under
the Securities Act by reason of a specific exemption from the registration provisions of the Securities Act, the availability of which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of Opus’
representations as expressed herein or otherwise made pursuant hereto. 
 4.2 Investment Intent. Opus is acquiring the Shares,
and the Conversion Shares, for investment for its own account, not as a nominee or agent, and not with the view to, or for resale in connection with, any distribution thereof, and that Opus has no present intention of selling, granting 

  
 6 

 
any participation in, or otherwise distributing the same. Opus further represents that it does not have any contract, undertaking, agreement or arrangement with any person or entity to sell,
transfer or grant participation to such person or entity or to any third person or entity with respect to any of the Shares or the Conversion Shares. Opus further represents and acknowledges that it became interested in acquiring the Shares and
the Conversion Shares as a result of a substantive, pre-existing relationship with the Company and direct contact with the Company and its agents outside of the Company’s efforts with respect to its initial public offering, that such interest
did not arise by means of either (i) any registration statement filed by the Company with the Securities and Exchange Commission (including the Registration Statement on Form S-1 (Registration No. 333-200293), as amended) or (ii) any
other general solicitation or any other means inconsistent with the availability of an exemption from registration under Section 4(a)(2) of the Securities Act, and that Opus was not contacted in connection with the marketing of the
Company’s initial public offering and did not independently contact the Company as a result of a general solicitation by means of any registration statement filed by the Company with the Securities and Exchange Commission. 

4.3 Investment Experience. Opus has substantial experience in evaluating and investing in private placement transactions of
securities in companies similar to the Company and acknowledges that Opus can protect its own interests. Opus has such knowledge and experience in financial and business matters so that Opus is capable of evaluating the merits and risks of its
investment in the Company. 
 4.4 Speculative Nature of Investment. Opus understands and acknowledges that the Company has a
limited financial and operating history and that an investment in the Company is highly speculative and involves substantial risks. Opus can bear the economic risk of its investment and is able, without impairing its financial condition, to hold the
Shares and the Conversion Shares for an indefinite period of time and to suffer a complete loss of its commitment. 
 4.5 Access to
Data. Opus has had an opportunity to ask questions of, and receive answers from, the officers of the Company concerning the Agreements, the exhibits and schedules attached hereto and thereto and the transactions contemplated by the
Agreements, as well as the Company’s business, management and financial affairs, which questions were answered to its satisfaction. Opus believes that it has received all the information it considers necessary or appropriate for deciding
whether to purchase the Shares and the Conversion Shares. Opus understands that such discussions, as well as any information issued by the Company, were intended to describe certain aspects of the Company’s business and prospects, but were not
necessarily a thorough or exhaustive description. Opus acknowledges that any business plans prepared by the Company have been, and continue to be, subject to change and that any projections included in such business plans or otherwise are
necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying the projections will not materialize or will vary significantly from actual results. Opus also acknowledges that it is relying solely on its own
counsel and not on any statements or representations of the Company or its agents for legal advice with respect to this investment or the transactions contemplated by the Agreements. The foregoing, however, does not limit or modify the
representations and warranties of the Company in Section 3 hereof and elsewhere in this Agreement or the right of Opus to rely thereon. 

4.6 Accredited Investor. Opus is an “accredited investor” within the meaning of Regulation D, Rule 501(a), promulgated
by the Securities and Exchange Commission under the Securities Act and shall submit to the Company such further assurances of such status as may be reasonably requested by the Company. 

  
 7 

 4.7 Rule 144. Opus acknowledges that the Shares and the Conversion Shares must be
held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available. Opus is aware of the provisions of Rule 144 promulgated under the Securities Act which permit resale of shares purchased
in a private placement subject to the satisfaction of certain conditions, which may include, among other things, the availability of certain current public information about the Company; the resale occurring not less than a specified period after a
party has purchased and paid for the security to be sold; the number of shares being sold during any three-month period not exceeding specified limitations; the sale being effected through a “brokers’ transaction,” a transaction
directly with a “market maker” or a “riskless principal transaction” (as those terms are defined in the Securities Act or the Exchange Act and the rules and regulations promulgated thereunder); and the filing of a Form 144
notice, if applicable. Opus acknowledges and understands that notwithstanding any obligation under the Rights Agreement, the Company may not be satisfying the current public information requirement of Rule 144 at the time Opus wishes to sell the
Shares or the Conversion Shares, and that, in such event, Opus may be precluded from selling such securities under Rule 144, even if the other applicable requirements of Rule 144 have been satisfied. Opus acknowledges that, in the event the
applicable requirements of Rule 144 are not met, registration under the Securities Act or an exemption from registration will be required for any disposition of the Shares or the underlying Common Stock. Opus understands that, although Rule 144 is
not exclusive, the Securities and Exchange Commission has expressed its opinion that persons proposing to sell restricted securities received in a private offering other than in a registered offering or pursuant to Rule 144 will have a substantial
burden of proof in establishing that an exemption from registration is available for such offers or sales and that such persons and the brokers who participate in the transactions do so at their own risk. 

4.8 No Public Market. Opus understands and acknowledges that no public market now exists for any of the securities issued by the
Company and that the Company has made no assurances that a public market will ever exist for the Company’s securities. 
 4.9
Authorization. 
 (a) Opus has all requisite power and authority to execute and deliver the Agreements, to purchase the Shares hereunder
and to carry out and perform its obligations under the terms of the Agreements. All action on the part of Opus necessary for the authorization, execution, delivery and performance of the Agreements, and the performance of all of its obligations
under the Agreements, has been taken or will be taken prior to the applicable Closing. 
 (b) The Agreements, when executed and delivered by
Opus, will constitute valid and legally binding obligations of Opus, enforceable in accordance with their terms except: (i) to the extent that the indemnification provisions contained in the Rights Agreement may be limited by applicable law and
principles of public policy, (ii) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, and (iii) as limited by laws
relating to the availability of specific performance, injunctive relief or other equitable remedies or by general principles of equity. 

  
 8 

 (c) No consent, approval, authorization, order, filing, registration or qualification of or with
any court, governmental authority or third person is required to be obtained by Opus in connection with the execution and delivery of the Agreements by Opus or the performance of its obligations hereunder or thereunder. 

4.10 Brokers or Finders. Opus has not engaged any brokers, finders or agents, and neither the Company nor Opus has, nor will, incur,
directly or indirectly, as a result of any action taken by Opus, any liability for brokerage or finders’ fees or agents’ commissions or any similar charges in connection with the Agreements. 

4.11 Tax Advisors. Opus has reviewed with its own tax advisors the U.S. federal, state, local and foreign tax consequences of this
investment and the transactions contemplated by the Agreements. With respect to such matters, Opus relies solely on such advisors and not on any statements or representations of the Company or any of its agents, written or oral. Opus understands
that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of this investment or the transactions contemplated by the Agreements. 

4.12 Legends. Opus understands and agrees that the certificates evidencing the Shares or the Conversion Shares, or any other securities
issued in respect of the Shares or the Conversion Shares upon any stock split, stock dividend, recapitalization, merger, consolidation or similar event, shall bear the following legend (in addition to any legend required by the Rights Agreement or
under applicable state securities laws): 
 “THE OFFER AND SALE OF THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE, AND SUCH SECURITIES MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SUCH ACT AND/OR APPLICABLE STATE SECURITIES LAWS, OR
UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.” 

4.13 No “Bad Actor” Disqualification Events. If Opus is (or, as a result of the exercise of its purchase of Shares hereunder,
will become) a beneficial owner of 20% or more of the Company’s outstanding voting securities, calculated on the basis of voting power, Opus affirms that none of (i) Opus, (ii) any of its directors, officers (as defined under Rule
16a-1 promulgated under the Exchange Act), other officers that may serve as a director or officer of the Company, general partners or managing members, nor (iii) any beneficial owner of Opus which is (or, as a result of the exercise of its
purchase of Shares hereunder, will become) a 20% beneficial owner of the voting securities of the Company (in accordance with Rule 506(d) of the Securities Act) is subject to any Disqualification Event (as defined in Section 3.13),
except for Disqualification Events covered by Rule 506(d)(2)(ii) or (iii) or (d)(3) under the Securities Act and disclosed reasonably in advance of the Closing in writing in reasonable detail to the Company. 

  
 9 

 SECTION 5 

Conditions to Opus’ Obligations to Close 

5.1 Conditions to Closing. Opus’ obligation to purchase the Shares at the Closing is subject to the fulfillment on or before the
Closing of each of the following conditions, unless waived in writing by Opus: 
 (a) Representations and Warranties. Except as set
forth in or modified by the Schedule of Exceptions, the representations and warranties made by the Company in Section 3 shall be true and correct in all material respects as of the date of the Closing. 

(b) Covenants. The Company shall have performed or complied with all covenants, agreements and conditions contained in this Agreement
to be performed or complied with by the Company on or prior to the Closing in all material respects. 
 (c) Blue Sky. The Company
shall have obtained all necessary Blue Sky law permits and qualifications, or have the availability of exemptions therefrom, required by any state for the offer and sale of the Shares and the Conversion Shares. 

(d) Rights Agreement. The Company, Opus, and the requisite Investors (as defined in the Rights Agreement) necessary to make the Rights
Agreement effective shall have executed and delivered the Rights Agreement on or prior to the date of the Closing. 
 (e) Closing
Deliverables. The Company shall have delivered to Opus a certificate executed by the Chief Executive Officer, President or Chief Financial Officer of the Company on behalf of the Company, in substantially the form of
Exhibit E, certifying the satisfaction of the conditions to closing listed in this Section 5.1. The Company shall also have delivered to Opus a certificate of the Secretary of the Company certifying (i) the Bylaws of the
Company, and (ii) resolutions of the Board of Directors of the Company approving the Agreements and the transactions contemplated under the Agreements. 

(f) Consents and Waivers. The Company shall have obtained any and all consents, permits and waivers necessary for consummation by the
Company of the transactions contemplated by the Agreements. 
 SECTION 6 

Conditions to Company’s Obligation to Close 

The Company’s obligation to sell and issue the Shares to Opus at the Closing is subject to the fulfillment on or before such Closing of the following
conditions, unless waived in writing by the Company: 
 6.1 Representations and Warranties. The representations and warranties made
by Opus in Section 4 shall be true and correct in all material respects when made and shall be true and correct in all material respects as of the date of the Closing. 

6.2 Covenants. Opus shall have performed or complied with all covenants, agreements and conditions contained in the Agreements to be
performed or complied with by Opus on or prior to the date of such Closing in all material respects. 

  
 10 

 6.3 Compliance with Securities Laws. The Company shall be satisfied that the offer and
sale of the Shares and the Conversion Shares shall be qualified or exempt from registration or qualification under all applicable federal and state securities laws (including receipt by the Company of all necessary blue sky law permits and
qualifications required by any state, if any). 
 6.4 Rights Agreement. The Company, Opus, and the requisite Investors (each as
defined in the Rights Agreement) necessary to make the Rights Agreement effective shall have executed and delivered the Rights Agreement on or prior to the date of the Closing. 

6.5 Consents and Waivers. Opus shall have obtained any and all consents, permits and waivers necessary for consummation by Opus of the
transactions contemplated by the Agreements. 
 6.6 License Agreement. The Effective Date of the License Agreement shall have
occurred. 
 6.7 Market Stand-off Agreement. Opus shall have executed and delivered the “market stand-off” agreement set
forth on Exhibit F on or prior to the date of the Closing. 
 SECTION 7 

Miscellaneous 
 7.1
Amendment. Except as expressly provided herein, neither this Agreement nor any term hereof may be amended, waived, discharged or terminated other than by a written instrument referencing this Agreement and signed by the Company and Opus. 

7.2 Notices. All notices and other communications required or permitted hereunder shall be in writing and shall be mailed by registered
or certified mail, postage prepaid, sent by facsimile or electronic mail or otherwise delivered by hand, messenger or courier service addressed: 

(a) if to Opus, to the attention of Chief Executive Officer at 537 Steamboat Road, Suite 200, Greenwich, CT 06830, or
Email: doug@opusbio.com, or at such other current address, fax or email as the Company shall have furnished to Opus, with a copy (which shall not constitute notice) to Thomas B. Rosedale, BRL Law Group LLC, 425 Boylston Street, Third Floor,
Boston, MA 02116; or 
 (b) if to the Company, to the attention of the General Counsel of the Company at 307 Westlake Avenue North, Suite
300, Seattle, WA 98109, or Email: barney.cassidy@junotherapeutics.com, or at such other current address or email as the Company shall have furnished to Opus, with a copy (which shall not constitute notice) to Patrick Schultheis, Wilson Sonsini
Goodrich & Rosati, P.C., 701 Fifth Avenue, Suite 5100, Seattle, WA 98104-7036. 
 Each such notice or other communication shall for all purposes of
this Agreement be treated as effective or having been given (i) if delivered by hand, messenger or courier service, when delivered (or if sent via a nationally-recognized overnight courier service, freight prepaid, specifying next-business-day
delivery, one business day after deposit with the courier), or (ii) if sent via mail, at the earlier of its receipt or five days after the same has been deposited in a regularly-maintained receptacle for the deposit of the United States mail,
addressed and mailed as aforesaid, or (iii) if sent via electronic mail, upon confirmation of delivery when directed to the relevant electronic mail 

  
 11 

 
address, if sent during normal business hours of the recipient, or if not sent during normal business hours of the recipient, then on the recipient’s next business day. In the event of any
conflict between the Company’s books and records and this Agreement or any notice delivered hereunder, the information on the signature page of this Agreement will control absent fraud or error. Subject to the limitations set forth in Delaware
General Corporation Law §232(e), Opus consents to the delivery of any notice to stockholders given by the Company under the Delaware General Corporation Law or the Company’s certificate of incorporation or bylaws by (i) facsimile
telecommunication to the facsimile number set forth in this Section 7.2 (or to any other facsimile number for Opus in the Company’s records), (ii) electronic mail to the electronic mail address set forth in this
Section 7.2 (or to any other electronic mail address for Opus in the Company’s records), (iii) posting on an electronic network together with separate notice to Opus of such specific posting or (iv) any other form of
electronic transmission (as defined in the Delaware General Corporation Law) directed to Opus. This consent may be revoked by Opus by written notice to the Company and may be deemed revoked in the circumstances specified in Delaware General
Corporation Law §232. 
 7.3 Governing Law. This Agreement shall be governed in all respects by the internal laws of the
State of Delaware as applied to agreements entered into among Delaware residents to be performed entirely within Delaware, without regard to principles of conflicts of law. 

7.4 Brokers or Finders. The Company shall indemnify and hold harmless Opus from any liability for any commission or compensation
in the nature of a brokerage or finder’s fee or agent’s commission (and the costs and expenses of defending against such liability or asserted liability) for which Opus or any of its constituent partners, members, officers, directors,
employees or representatives is responsible to the extent such liability is attributable to any inaccuracy or breach of the representations and warranties contained in Section 3.15, and Opus agrees to indemnify and hold harmless the
Company from any liability for any commission or compensation in the nature of a brokerage or finder’s fee or agent’s commission (and the costs and expenses of defending against such liability or asserted liability) for which the Company
or any of its constituent partners, members, officers, directors, employees or representatives is responsible to the extent such liability is attributable to any inaccuracy or breach of the representations and warranties contained in
Section 4.10. 
 7.5 Expenses. The Company and Opus shall each pay their own expenses in connection with the
transactions contemplated by this Agreement. 
 7.6 Survival. The representations, warranties, covenants and agreements made in
this Agreement shall survive any investigation made by either party hereto and the closing of the transactions contemplated hereby for one year from the date of the applicable Closing. 

7.7 Successors and Assigns. This Agreement, and any and all rights, duties and obligations hereunder, shall not be assigned,
transferred, delegated or sublicensed by Opus without the prior written consent of the Company. Any attempt by Opus without such permission to assign, transfer, delegate or sublicense any rights, duties or obligations that arise under this Agreement
shall be void. Subject to the foregoing and except as otherwise provided herein, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto.

  
 12 

 7.8 Entire Agreement. This Agreement, including the exhibits attached hereto,
constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof. No party shall be liable or bound to any other party in any manner with regard to the subjects hereof or thereof by any
warranties, representations or covenants except as specifically set forth herein or therein. 
 7.9 Delays or Omissions. Except
as expressly provided herein, no delay or omission to exercise any right, power or remedy accruing to any party to this Agreement upon any breach or default of any other party under this Agreement shall impair any such right, power or remedy of such
non-defaulting party, nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed
a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any
party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party to
this Agreement, shall be cumulative and not alternative. 
 7.10 California Corporate Securities Law. THE SALE OF THE SECURITIES
THAT ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION THEREFOR PRIOR TO SUCH
QUALIFICATION IS UNLAWFUL UNLESS THE SALE OF SECURITIES IS EXEMPT FROM QUALIFICATION BY SECTION 25100, 25102, OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED UPON THE
QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT. 
 7.11 Severability. If any provision of this Agreement becomes or
is declared by a court of competent jurisdiction to be illegal, unenforceable or void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Agreement, and such court will replace such
illegal, void or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the same economic, business and other purposes of the illegal, void or unenforceable provision. The balance
of this Agreement shall be enforceable in accordance with its terms. 
 7.12 Counterparts. This Agreement may be executed in any
number of counterparts, each of which shall be enforceable against the parties actually executing such counterparts, and all of which together shall constitute one instrument. 

7.13 Telecopy Execution and Delivery. A facsimile, telecopy or other reproduction of this Agreement may be executed by one or more
parties hereto and delivered by such party by facsimile or any similar electronic transmission device pursuant to which the signature of or on behalf of such party can be seen. Such execution and delivery shall be considered valid, binding and
effective for all purposes. At the request of any party hereto, all parties hereto agree to execute and deliver an original of this Agreement as well as any facsimile, telecopy or other reproduction hereof. 

  
 13 

 7.14 Jurisdiction; Venue. With respect to any disputes arising out of or related to
this Agreement, the parties consent to the exclusive jurisdiction of, and venue in, the state courts in Wilmington, Delaware (or in the event of exclusive federal jurisdiction, the federal courts in Wilmington, Delaware). 

7.15 Further Assurances. Each party hereto agrees to execute and deliver, by the proper exercise of its corporate, limited
liability company, partnership or other powers, all such other and additional instruments and documents and do all such other acts and things as may be necessary to more fully effectuate this Agreement. 

7.16 Attorney’s Fees. In the event that any suit or action is instituted to enforce any provisions in this Agreement, the
prevailing party in such dispute shall be entitled to recover from the losing party such reasonable fees and expenses of attorneys and accountants, which shall include, without limitation, all fees, costs and expenses of appeals. 

7.17 Jury Trial. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY AND ALL RIGHT
TO TRIAL BY JURY IN ANY LEGAL PROCEEDING (WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATED TO THIS AGREEMENT. 

7.18 Waiver of Potential Conflicts of Interest. Opus and the Company acknowledge that Wilson Sonsini Goodrich & Rosati,
Professional Corporation (“WSGR”) may have represented and may currently represent Opus or its affiliates. In the course of such representation, WSGR may have come into possession of confidential information relating to Opus.
Opus and the Company acknowledge that WSGR is representing only the Company in this transaction. Pursuant to Rule 3-310 of the Rules of Professional Conduct promulgated by the State Bar of California, an attorney must avoid representations in which
the attorney has or had a relationship with another party interested in the representation without the informed written consent of all parties affected. By executing this Agreement, Opus and the Company hereby waive any actual or potential conflict
of interest which may arise as a result of WSGR’s representation of Opus or its affiliates and WSGR’s possession of such confidential information. Each of Opus and the Company represents that it has had the opportunity to consult with
independent counsel concerning the giving of this waiver. 
 (signature page follows) 

  
 14 

 The parties are signing this Stock Purchase Agreement as of the date stated in the introductory
clause. 
  

			
	 JUNO THERAPEUTICS, INC.
 a
Delaware corporation

		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

  

			
	 OPUS BIO, INC.
 a Delaware
corporation

		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

  
 15 

 EXHIBIT D 

MARKET STAND-OFF AGREEMENT 

[ATTACHED] 

  
 16 

 LOCK-UP LETTER 

                    , 2014 

Morgan Stanley & Co. LLC 
 J.P. Morgan Securities LLC

 Goldman, Sachs & Co. 
 as
Representatives of the several Underwriters named in 
 Schedule I to the Underwriting Agreement referred to below 

c/o Morgan Stanley & Co. LLC 
 1585
Broadway 
 New York, NY 10036 
 c/o J.P.
Morgan Securities LLC 
 383 Madison Avenue 

New York, NY 10179 
 c/o Goldman,
Sachs & Co. 200 
 West Street 

New York, NY 10282 
 Ladies and Gentlemen: 

The undersigned understands that Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC and Goldman, Sachs & Co. (the
“Representatives”) propose to enter into an Underwriting Agreement (the “Underwriting Agreement”) with Juno Therapeutics, Inc., a Delaware corporation (the “Company”), providing for the public offering (the “Public
Offering”) by the several Underwriters, including the Representatives (the “Underwriters”), of shares (the “Shares”) of the common stock, par value $0.0001 per share of the Company (the “Common Stock”). 

To induce the Underwriters that may participate in the Public Offering to continue their efforts in connection with the Public Offering, the
undersigned hereby agrees that, without the prior written consent of the Representatives on behalf of the Underwriters, it will not, during the period commencing on the date hereof and ending on, and including, the date that is 180 days after the
effective date of the registration statement (the “Restricted Period”) relating to the Public Offering (the “Prospectus”), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any
option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock beneficially owned (as such term is used in Rule 13d-3 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”)), by the undersigned or any other securities so owned convertible into or exercisable or exchangeable for Common Stock or (2) enter into any swap or other arrangement that
transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Common Stock or such other
securities, in cash or otherwise. 

  
 17 

 The foregoing sentence shall not apply to: 

(a) transactions relating to shares of Common Stock or other securities sold or acquired in the Public Offering (other than any
issuer-directed shares of Common Stock purchased in the Public Offering by an officer or director of the Company) or acquired in open market transactions after the completion of the Public Offering, provided that no filing under
Section 16(a) of the Exchange Act shall be required or shall be voluntarily made in connection with subsequent sales of Common Stock or other securities acquired in such open market transactions; 

(b) transfers of shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock (i) by will or
intestacy, (ii) by bona fide gift, (iii) to the spouse, domestic partner, parent, child or grandchild (each, an “immediate family member”) of the undersigned or to a trust formed for the benefit of one or more immediate family
members, (iv) if the undersigned is a corporation, partnership or other business entity (x) to another corporation, partnership or other business entity that controls, is controlled by or is under common control with the undersigned or
(y) as part of a disposition, transfer or distribution without consideration by the undersigned to its equity holders, limited partners or members or (v) if the undersigned is a trust, to a trustee or beneficiary of the trust, provided
that in the case of any transfer or distribution pursuant to this clause (b), each transferee, donee or distributee shall execute and deliver to the Representatives a lock-up letter substantially in the form of this Letter Agreement, and
provided, further, in the case of clauses (ii) through (v), that no filing under Section 16(a) of the Exchange Act reporting a reduction in beneficial ownership of shares of Common Stock or other public announcement shall be
required or shall be voluntarily made during the Restricted Period (provided, however, that the undersigned shall be permitted to make required filings on a Schedule 13D, Form 13F or Schedule 13G under the Exchange Act, provided that any such
filings shall not be made in connection with a transfer, disposition or distribution of Common Stock or any security convertible into or exercisable of exchangeable for Common Stock); 

(c) the transfer of shares of Common Stock or any securities convertible into Common Stock to the Company upon a vesting event of the
Company’s securities or upon the exercise of options or warrants to purchase the Company’s securities, in each case on a “cashless” or “net exercise” basis or to cover tax withholding obligations of the undersigned in
connection with such vesting or exercise, provided that the underlying shares of Common Stock continue to be subject to the restrictions set forth in this Letter Agreement and, provided, further, that no filing under
Section 16(a) of the Exchange Act reporting a disposition of shares of Common Stock or other public announcement shall be required or shall be made voluntarily in connection with such vesting or exercise during the Restricted Period; 

(d) the exercise of options for cash to purchase shares of Common Stock granted under a stock incentive plan or stock purchase plan described
in the Prospectus, or the exercise of warrants for cash to purchase shares of Common Stock described in the Prospectus and outstanding as of the date of the Prospectus, provided, that the underlying shares of Common Stock continue to be
subject to the restrictions set forth in this Letter Agreement; 
 (e) the establishment of a trading plan pursuant to Rule 10b5-1 under the
Exchange Act for the transfer of shares of Common Stock, provided that (i) such plan does not provide for the transfer of Common Stock during the Restricted Period and (ii) to the extent a public

  
 18 

 
announcement or filing under the Exchange Act regarding the establishment of such plan is required of or is voluntarily made by or on behalf of the undersigned or the Company, such announcement
or filing shall include a statement to the effect that no transfer of Common Stock may be made under such plan during the Restricted Period; 

(f) the conversion of the outstanding preferred stock of the Company into shares of Common Stock, provided that such shares of Common
Stock remain subject to the terms of this Letter Agreement; 
 (g) the transfer of shares of Common Stock or any security convertible into
or exercisable or exchangeable for Common Stock to the Company, pursuant to agreements under which the Company has the option to repurchase such shares or a right of first refusal with respect to transfers of such shares; 

(h) the transfer of shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock that occurs by
operation of law, such as pursuant to a qualified domestic order or in connection with a divorce settlement; provided that (i) with respect to any transfer in connection with a divorce settlement, each transferee shall execute and
deliver to the Representatives a lock-up letter substantially in the form of this Letter Agreement and (ii) to the extent a public announcement or filing under the Exchange Act regarding the transfer is required of or is voluntarily made by or
on behalf of the undersigned or the Company, such announcement or filing shall include a statement to the effect that the transfer was made by operation of law and, if applicable, pursuant to a qualified domestic order or in connection with a
divorce settlement, as applicable; 
 (i) the transfer of shares of Common Stock or any security convertible into or exercisable or
exchangeable for Common Stock pursuant to a bona fide third party tender offer, merger, consolidation or other similar transaction made to all holders of the Common Stock involving a change of control of the Company (including, without limitation,
entering into any lock-up, voting or similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of Common Stock or such other securities in connection with any such transaction, or vote any
securities in favor of any such transaction) that has been approved by the board of directors of the Company, provided that if the tender offer, merger, consolidation or other such transaction is not completed, the Common Stock owned by the
undersigned shall remain subject to the restrictions contained in this Letter Agreement; or 
 (j) the exercise of any right with respect
to, or the taking of any other action in preparation for, a registration by the Company of shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, provided that no transfer of the
undersigned’s Common Stock registered pursuant to the exercise of such rights under this item shall occur, and no registration statement shall be filed, during the Restricted Period. 

For the purposes of clause (i), a “change of control” means the transfer (whether by tender offer, merger, consolidation or
other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons (other than the Underwriters pursuant to the Public Offering), of shares of Common Stock or any securities convertible
into or exercisable or exchangeable for Common Stock if, after such transfer, the stockholders of the Company immediately prior to such transfer do not own a majority of the outstanding voting securities of the Company (or the surviving entity).

  
 19 

 In addition, the undersigned agrees that, subject to the exception set forth in paragraph
(j) above, without the prior written consent of the Representatives on behalf of the Underwriters, it will not, during the Restricted Period, make any demand for or exercise any right with respect to, the registration of any shares of Common
Stock or any security convertible into or exercisable or exchangeable for Common Stock. The undersigned also agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of
the undersigned’s shares of Common Stock except in compliance with the foregoing restrictions. 
 If the undersigned is an officer or
director of the Company, the undersigned further agrees that the foregoing provisions shall be equally applicable to any issuer-directed Shares the undersigned may purchase in the Public Offering. 

If the undersigned is an officer or director of the Company, (i) the Representatives agree that, at least three business days before the
effective date of any release or waiver of the foregoing restrictions in connection with a transfer of shares of Common Stock, the Representatives will notify the Company of the impending release or waiver, and (ii) the Company has agreed in
the Underwriting Agreement to announce the impending release or waiver by press release through a major news service at least two business days before the effective date of the release or waiver. Any release or waiver granted by the Representatives
hereunder to any such officer or director shall only be effective two business days after the publication date of such press release. The provisions of this paragraph will not apply if (a) the release or waiver is effected solely to permit a
transfer not for consideration and (b) the transferee has agreed in writing to be bound by the same terms described in this Letter Agreement to the extent and for the duration that such terms remain in effect at the time of the transfer. 

By accepting the obligations of the undersigned contained herein, each of the Representatives, on behalf of the underwriters, agrees that if
the Representatives waive or terminate any of the foregoing restrictions in connection with a transfer of capital stock of the Company, with respect to any of the securities of any executive officer or director of the Company or person that held at
least 1% of the Common Stock prior to the Public Offering (calculated on an as-converted, fully-diluted basis and as of the close of business on the date set forth on the final prospectus used to sell the Shares) (a “Triggering
Release”), the provisions of this letter agreement shall be waived or terminated, as applicable, to the same extent and on the same terms with respect to the same pro rata percentage of securities of the undersigned as the percentage of
Common Stock being released in the Triggering Release represent with respect to the securities held by the applicable executive officer, director or greater-than-1% stockholder. Notwithstanding the foregoing, no waiver or termination will constitute
a Triggering Release, if (a) the aggregate fair market value of such releases to such security holders (whether in one or multiple releases) is less than or equal to $1,000,000 in the aggregate (such fair market value to be calculated using the
closing or last reported sale price of the Common Stock on the date of each such release) or (b) such waiver or termination, in full or in part, is in connection with any underwritten public offering, whether or not such offering or sale is
wholly or partially a secondary offering of the Common Stock during the Restricted Period (a “Follow-on Offering”); provided that the undersigned, to the extent the undersigned has a contractual right to demand or require the
registration of the undersigned’s Common Stock or otherwise “piggyback” on a registration statement filed by the Company for 

  
 20 

 
the offer and sale of its Common Stock, (i) shall be offered the opportunity to participate on a pro rata basis consistent with such contractual rights in such Follow-on Offering and on
pricing terms that are no less favorable than the terms of the Follow-on Offering or (ii) such contractual rights are waived pursuant to the terms thereof; and in the event the Underwriters make the determination to cut back the number of
securities to be sold by stockholders in the Follow-on Offering, such cut back shall be on a basis consistent with such contractual rights. 

The undersigned understands that the Company and the Underwriters are relying upon this Letter Agreement in proceeding toward consummation of
the Public Offering. The undersigned further understands that this Letter Agreement is irrevocable and shall be binding upon the undersigned’s heirs, legal representatives, successors and assigns. 

Whether or not the Public Offering actually occurs depends on a number of factors, including market conditions. Any Public Offering will only
be made pursuant to an Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Underwriters. 

The undersigned understands that, (i) if either the Representatives, on the one hand, or the Company, on the other hand, informs the
other, prior to the execution of the Underwriting Agreement, that it has determined not to proceed with the Public Offering, (ii) if the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be
terminated prior to payment for and delivery of the Securities to be sold thereunder, (iii) if the registration statement related to the Public Offering has been withdrawn prior to the execution of the Underwriting Agreement or (iv) the
Underwriting Agreement is not executed on or before March 31, 2015, the undersigned shall be automatically released from all obligations under this Letter Agreement. 

This Letter Agreement and any claim, controversy or dispute arising under or related to this Letter Agreement shall be governed by and
construed in accordance with the laws of the State of New York, without regard to the conflict of laws principles thereof. 
  

	
	 Very truly yours,

	
	 (Name)

	
	 (Address)

  
 21 

 EXHIBIT E 

BENCHMARKS 
  

					
	I.	  	[***]	  	[***]
	II.	  	[***]	  	[***]
	III.	  	[***]	  	[***]
	IV.	  	[***]	  	[***]
	V.	  	[***]	  	[***]

  
 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}]]